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Anxiety and substance use disorders rank among the most common and difficult to treat co-
occurring psychiatric conditions in the Western world. This dissertation sought to better 
understand the relationship between these disorders and how they impact one-another. To meet 
this aim, this dissertation explored data from a study conducted by Velasquez and colleagues (in 
press), known as Project TIP (Traumatic Injury Prevention). Because Project TIP demographics 
were similar to demographics found among the military, this dissertation was able to draw 
parallels between the two populations and generate findings applicable to both the general public 
and the military.   
This study addressed two primary questions. First, does anxiety impact substance use 
outcomes; and second, how does anxiety impact the process of change for substance use? T-tests, 
general linear model (GLM) profile analyses, GLM repeated measures analyses, and latent 
growth curve analyses were used to test hypotheses that: 1) increased anxiety would negatively 
impact substance use outcomes; 2) anxiety and non-anxiety groups would experience substance 
use change differently; and 3) those with anxiety would differ in their trajectory (degree of 
change) in accordance with Transtheoretical Model (TTM) constructs over time.  
Several key findings emerged from this dissertation. The first was that anxiety’s impact 
on substance use was drug dependent, which indicates future research should compare specific 
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substances or categories of substances, rather than lumping all substances into a single category. 
Additionally, the two groups experienced change in different ways in accordance with TTM 
constructs, which were also substance dependent. Primarily, the anxiety group maintained a 
higher state of readiness to change across the study, but never overcame their perceived cons for 
change or temptations to return to use. Overall, while both groups’ substance use improved to a 
similar degree, prior research suggests that because the anxiety group reported an overall higher 
readiness to change, the anxiety group could have changed at a greater rate, had their self-
efficacy concerns been addressed. Therefore, clinicians should avoid the “one size fits all” 
approach and endeavor to tailor treatment regimens for those with anxiety. 
viii 
 
Table of Contents 
List of Tables ....................................................................................................... xiii 
List of Figures ........................................................................................................xv 
I. INTRODUCTION ...............................................................................................1 
Problem Statement ...................................................................................................1 
TRANSTHEORETICAL MODEL (TTM).....................................................................3 
Key Concepts and Terms .........................................................................................8 
SUBSTANCE MISUSE AND DISORDERS ...................................................................10 
Substance Misuse. ..................................................................................................10 
Substance Abuse. ..........................................................................................10 
Substance Dependence..................................................................................11 
Substance vs Drug.........................................................................................14 
Categories of Substances & Epidemiology ............................................................15 
Alcohol. .........................................................................................................15 







MILITARY SUB POPULATION ................................................................................29 
Substance Abuse and the Military .........................................................................30 
Anxiety and the Military ........................................................................................31 
Co-occurrence of Disorders in the Military ...........................................................32 
II. THEORY & TREATMENT OF CO-OCCURRING DISORDERS ..........................34 
Sequential Treatment .............................................................................................34 
Parallel Treatment ..................................................................................................35 
Integrated Treatment ..............................................................................................36 
Anxiety and the Transtheoretical Model................................................................37 
III. GAPS IN THE LITERATURE ...........................................................................39 
IV. CURRENT STUDY ..........................................................................................41 
Research Questions, Hypotheses, and Proposed Analysis.....................................41 
Research Question 1. ....................................................................................41 
Hypothesis 1a. ......................................................................................41 
Analysis................................................................................................41 
Research Question 2. ....................................................................................42 







Study Design and Treatment Intervention .............................................................44 
Sample....................................................................................................................45 
Measures and Study Variables ...............................................................................49 
Sociodemographic Factors. ...........................................................................49 
Anxiety. .........................................................................................................49 
Substance Use. ..............................................................................................50 
Transtheoretical Model (TTM) Instruments. ................................................51 
Process of Change Questionnaire (PCQ). ............................................51 
Abstinence Self-Efficacy Scale (ASE). ...............................................51 
Decisional Balance (DB) Scale. ...........................................................52 
University of Rhode Island Change Assessment (URICA) Scale. ......52 
PRELIMINARY DATA SCREENING .........................................................................53 
Missing Data ..........................................................................................................53 
Outliers and Violations of Normality ....................................................................54 
V. RESULTS .......................................................................................................55 
Baseline T-tests for Substance Use Outcomes.......................................................55 
Repeated Measures for Substance Use Outcomes .................................................57 
Profile Analyses .....................................................................................................63 
CANNABIS ...............................................................................................................63 
Cocaine ..................................................................................................................71 




Latent Growth Curve (LGC) Analyses ..................................................................78 
Cannabis Confidence and Temptation ...................................................................79 
Conceptual Model .........................................................................................79 
xi 
 
Level 1. .........................................................................................................81 
Level 2. .........................................................................................................83 
Cannabis Decisional Balance .................................................................................84 
Conceptual Model. ........................................................................................84 
Level 1. .........................................................................................................86 
Level 2. .........................................................................................................88 
Cannabis Processes of Change...............................................................................89 
Conceptual Model. ........................................................................................89 
Level 1. .........................................................................................................91 
Level 2. .........................................................................................................93 
Cannabis Readiness ...............................................................................................94 
Conceptual/Level 1 Model. ...........................................................................94 
Level 2. .........................................................................................................96 
Cocaine Conf and Temp ......................................................................................100 
Conceptual Model. ......................................................................................100 
Level 1. .......................................................................................................101 
Level 2. .......................................................................................................103 
Cocaine Decisional Balance ................................................................................104 
Conceptual Model .......................................................................................104 
Level 1. .......................................................................................................106 
Level 2. .......................................................................................................108 
Cocaine Processes of Change ..............................................................................109 
Conceptual Model. ......................................................................................109 
Level 1. .......................................................................................................111 
Level 2. .......................................................................................................113 
Cocaine Readiness ...............................................................................................114 
Conceptual/level 1 Model. ..........................................................................114 
Level 2. .......................................................................................................117 
xii 
 
VI. DISCUSSION .................................................................................................120 
Anxiety’s Impact on Substance Use Outcomes ...................................................121 
Anxiety’s Impact on the Process of Changing Substance Use ............................124 
Profile Differences Between Substances .............................................................130 
Implications for Practice ......................................................................................132 
Implications for the Military ................................................................................134 
Limitations and Future Research Directions ........................................................136 





List of Tables 
Table 1.1 The Experiential and Behavioral Processes of Change and Their Associated 
Stage of Change ..................................................................................7 
Table 1.2 Substance use definitions ..................................................................13 
Table 4.1 Study Sample Demographics ............................................................48 
Table 5.1 Baseline t-tests comparing anxiety and non-anxiety groups on substance use 56 
Table 5.2 PDA means by anxiety group for all substances at baseline ............56 
Table 5.3 Interaction between anxiety groups across PDA Substance Use Outcomes over 
time ....................................................................................................57 
Table 5.4 Comparison of Anxiety versus Non-anxiety groups on PDA for alcohol: 
baseline, 3-, 6-, and 12-months .........................................................58 
Table 5.5 Comparison of Anxiety versus Non-anxiety groups on PDA for any drug: 
baseline, 3-, 6-, and 12-months .........................................................59 
Table 5.6 Comparison of Anxiety versus Non-anxiety groups on PDA for cannabis: 
baseline, 3-, 6-, and 12-months .........................................................60 
Table 5.7 Comparison of Anxiety versus Non-anxiety groups on PDA for cocaine: 
baseline, 3-, 6-, and 12-months .........................................................61 
Table 5.8 Main Effect for Percent Days Abstinent by Substance .....................62 
Table 5.9 Time Effects for Percent Days Abstinent by Substance ....................62 
Table 5.10 TTM Constructs Multivariate Tests for parallelism for Cannabis ...64 
Table 5.11 Baseline TTM Construct Parameter Estimates of Between Subjects Effects for 
Cannabis ...........................................................................................65 
Table 5.12 3 Month TTM Construct Parameter Estimates of Between Subjects Effects for 
Cannabis ...........................................................................................66 




Table 5.14 12 Month TTM Construct Parameter Estimates of Between Subjects Effects for 
Cannabis ...........................................................................................69 
Table 5.15 TTM Constructs Multivariate Tests of Parallelism for Cocaine ......71 
Table 5.16 Baseline TTM Construct Parameter Estimates of Between Subjects Effects for 
Cocaine .............................................................................................72 
Table 5.17 3 Month TTM Construct Parameter Estimates of Between Subjects Effects for 
Cocaine .............................................................................................73 
Table 5.18 6 Month TTM Construct Parameter Estimates of Between Subjects Effects for 
Cocaine .............................................................................................75 
Table 5.19 12 Month TTM Construct Parameter Estimates of Between Subjects Effects for 
Cocaine .............................................................................................76 
Table 5.20 LGC Cannabis Self-Efficacy TTM Variable Modification Table .....80 
Table 5.21 LGC Cannabis DB TTM Variable Modification Table.....................85 
Table 5.22 LGC Cannabis POC TTM Variable Modification Table ..................90 
Table 5.23 LGC Cannabis Readiness TTM Variable Modification Table ..........95 
Table 5.24 LGC Summary Table of TTM constructs for cannabis .....................99 
Table 5.25 LGC Cocaine Self-Efficacy TTM Variable Modification Table .....100 
Table 5.26 LGC Cocaine DB TTM Variable Modification Table.....................105 
Table 5.27 LGC Cocaine POC TTM Variable Modification Table ..................110 
Table 5.28 LGC Cocaine Readiness TTM Variable Modification Table ..........116 
Table 5.29 LGC Summary Table of TTM constructs for cocaine .....................119 
xv 
 
List of Figures 
Figure 4.1: Participant Flow Chart ......................................................................46 
Figure 5.1: PDA for alcohol between anxiety and non-anxiety groups over time 58 
Figure 5.2: PDA for any drug between anxiety and non-anxiety groups over time59 
Figure 5.3: PDA for cannabis between anxiety and non-anxiety groups over time60 
Figure 5.4: PDA for cocaine between anxiety and non-anxiety groups over time61 
Figure 5.5: Baseline mean differences in TTM constructs between anxiety and non-anxiety 
groups for cannabis ...........................................................................65 
Figure 5.6: 3-month mean differences in TTM constructs between anxiety and non-anxiety 
groups for cannabis ...........................................................................67 
Figure 5.7: 6-month mean differences in TTM constructs between anxiety and non-anxiety 
groups for cannabis ...........................................................................68 
Figure 5.8: 12-month mean differences in TTM constructs between anxiety and non-anxiety 
groups for cannabis ...........................................................................70 
Figure 5.9: Mean differences in TTM constructs between anxiety and non-anxiety groups at 
baseline for cocaine...........................................................................72 
Figure 5.10: Mean differences in TTM constructs between anxiety and non-anxiety groups at 
3 months for cocaine .........................................................................74 
Figure 5.11: Mean differences in TTM constructs between anxiety and non-anxiety groups at 
6 months for cocaine .........................................................................75 
Figure 5.12: Mean differences in TTM constructs between anxiety and non-anxiety groups at 
12 months for cocaine .......................................................................77 
Figure 5.13: Level 1, base model of Confidence and Temptation for cannabis ....81 
Figure 5.14: Level 1, model 3 of Confidence and Temptation for cannabis .........83 
Figure 5.15: Level 2, model 4 of Confidence and Temptation for cannabis .........84 
Figure 5.16: Level 1, base model of Decisional Balance for cannabis .................86 
xvi 
 
Figure 5.17: Level 1, model 3 of Decisional Balance for cannabis ......................88 
Figure 5.18: Level 2, model 4 of Decisional Balance for cannabis ......................89 
Figure 5.19: Level 1, base model of Processes of Change for cannabis ...............91 
Figure 5.20: Level 1, model 3 of Processes of Change for cannabis ....................93 
Figure 5.21: Level 2, model 4 of Processes of Change for cannabis ....................94 
Figure 5.22: Level 1, base model of Readiness for cannabis ................................96 
Figure 5.23: Level 2, model 4 of Readiness for cannabis .....................................98 
Figure 5.24: Level 1, base model of Confidence and Temptation for cocaine ...101 
Figure 5.25: Level 1, model 3 of Confidence and Temptation for cocaine.........103 
Figure 5.26: Level 2, model 4 of Confidence and Temptation for cocaine.........104 
Figure 5.27: Level 1, base model of Decisional Balance cocaine .......................106 
Figure 5.28: Level 1, model 3 of Decisional Balance for cocaine ......................108 
Figure 5.29: Level 2, model 4 of Decisional Balance for cocaine ......................109 
Figure 5.30: Level 1, base model of Processes of Change for cocaine ...............111 
Figure 5.31: Level 1, model 3 of Processes of Change for cocaine ....................113 
Figure 5.32: Level 2, model 4 of Processes of Change for cocaine ....................114 
Figure 5.33: Level 1, base model of Readiness for cocaine ................................116 





Of all the psychiatric disorders, few are as prevalent as substance use (alcohol and other 
drug) disorders (SUD) and anxiety disorders (AD) (Grant et al., 2004). In the United States, 
lifetime rates are estimated to be 14.6% for SUD and 28.8% for AD (Kessler et al., 2005). ADs 
and SUDs are among the most common psychiatric conditions in the Western world, affecting 
every demographic group and exacting a profound cost on individuals and society as a whole. 
For the individual, these costs include negative impacts on employment opportunities, harm to 
personal and professional relationships, and an overall decrease in quality of life. Meanwhile, 
society also feels the burden through increased criminal activity, loss of labor, and significant 
strains on over-burdened medical and mental health systems (Rippeth, 2007; Simpson et al., 
2010). These concerns are further compounded by the fact that SUDs and ADs often occur 
together (Wyman & Castle, 2006). 
Decades of research show that SUDs and ADs co-occur at far greater rates than would be 
expected by chance (Smith & Book, 2008). Also, findings clearly reveal that the presence of an 
AD or a SUD is also a risk factor for the other disorder, which both epidemiological and clinical 
samples demonstrate (Kushner, Krueger, Frye, & Peterson, 2008; Kushner, Sher, & Beitman, 
1990). As a result, researchers and clinicians have sought to examine this co-morbid relationship, 
particularly due to its high prevalence, developmental and maintenance characteristics, clinical 
impact, and unique treatment factors (Smith & Book, 2008). 
Problem Statement  
Despite the undeniable individual and societal impacts observed as a result of these co-
occurring conditions, research in this area remains insufficient, especially in regard to providing 
treatment recommendations for dually diagnosed patients. For example, researchers have yet to 
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reach a consensus on diagnostic procedures for either disorder, which approaches or models are 
most effective for treating them, or whether these conditions should be treated simultaneously or 
sequentially (Smith & Randall, 2012). In part, this lack of consensus likely remains due to the 
current focus of research on seeking effective treatments for the two disorders separate from one 
another. Therefore, to further address co-occurring ADs and SUDS, it will be necessary to 
examine the nature of each disorder’s impact on the other, particularly in regard to processes of 
change. Furthermore, specific subpopulations are likely to be far more affected by the 
comorbidity of these conditions than others. For instance, members of the military, who are 
significantly more prone to a lifetime occurrence of substance abuse and anxiety disorders than 
the general population (Bray et al., 2010; Lane, Hourani, Bray & Williams, 2012), would greatly 
benefit from increased attention to comorbid ADs and SUDS. Therefore, this dissertation 
includes a discussion of the military as a target subpopulation.  
Of the many theoretical approaches to understanding SUDs and behavior change, one of 
the most prominent is the Transtheoretical Model (TTM) of behavioral change. This dynamic 
model describes behavior change though a biopsychosocial approach and is highly effective at 
predicting behavior change in SUDs and many other problems (Prochaska & DiClemente, 1984), 
making this model ideal for the purposes of this dissertation. Guided by Prochaska and 
DiClemente’s (1984) TTM, this dissertation examines the co-morbid relationship between 
anxiety and substance use disorders, particularly in regard to the processes of change as 
described in the TTM. Specifically, this dissertation endeavors to address how anxiety relates to 
substance use outcomes.  
To this end, this dissertation will first describe substance use and anxiety disorders in 
detail, including comorbid etiology and treatment. Next, gaps found in the literature will be 
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discussed, followed by several research questions and accompanying hypotheses. Lastly, the 
paper describes the statistical methods used to address the research questions and accompanying 
hypotheses in order to explore the impacts of anxiety on substance use outcomes, particularly in 
regard to the processes of change described in the transtheoretical model.  
TRANSTHEORETICAL MODEL (TTM) 
In the 1980s by Prochaska and DiClemente (1984), developed the transtheoretical model 
as a theory of behavior change that has successfully predicted change in a variety of situations 
including alcoholism treatment (Prochaska et al., 2004), smoking/tobacco cessation (Wagner, 
Burg, & Sirois, 2004), cocaine addiction group treatment (Velasquez et al., 2001), STI screening 
(Chacko et al., 2003), and safer sexual behaviors (White et al., 2001; Redding et al., 1996). The 
model was created by integrating processes and principles of change from across leading theories 
of behavior change, which is why it is called the transtheoretical model (Prochaska, DiClemente, 
& Norcross, 1992). The TTM approaches behavior change as a dynamic, rather than static, 
process. In other words, rather than only focusing on behavior change when the client is actively 
pursuing change, this model demonstrates a framework for understanding, measuring, and 
intervening in behavior change throughout the change process from the period before change has 
commenced to the period when change is being maintained (Marshall & Biddle, 2001; Velicer et 
al., 1998). TTM contains several core constructs including stages of change, processes of 
change, decisional balance, and self-efficacy and temptation. 
Stages of Change. TTM describes behavior change as an internal model that transpires 
over time through six stages of change. These are precontemplation, contemplation, preparation, 
action, maintenance, and termination, although the literature generally cites only the first four 
stages as the primary stages of change (Prochaska, 2013). 
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Precontemplation. This is the first stage in the process and accounts for the point at 
which individuals are not intending to take action toward making a change in the foreseeable 
future. This stage is often misunderstood to mean that these people do not want to change. One 
reason individuals remain in this stage is due to a lack of awareness of the health or other 
negative consequences of a behavior. Additionally, they may be demoralized about their abilities 
to change, possibly having failed to change a behavior in the past. In other words, they may want 
to change, but they doubt their ability to change (Prochaska, 2013; Prochaska & DiClemente, 
1982; Prochaska & Velicer, 1997).  
Contemplation. This stage describes individuals who are thinking about change but have 
not yet decided whether or not they will change.  These individuals are likely aware of the 
benefits of changing, but may also be aware of the cons, such as giving up benefits of the 
behavior, or perhaps facing failure. In this stage, individuals continually weigh both the pros and 
the cons of behavior change (Prochaska, 2013; Prochaska & DiClemente, 1982; Prochaska & 
Velicer, 1997; Velasquez et al., 2015).  
Preparation. In the preparation stage, individuals have determined that the pros of 
change outweigh the cons (Velasquez et al., 2015) and intend to take immediate action. Ensuring 
the individual is sufficiently equipped to make the desired change is essential at this stage.  The 
more prepared an individuals are in this stage, the more likely they are to reach their goal 
(Prochaska, 2013; Prochaska & DiClemente, 1982; Prochaska & Velicer, 1997; Velasquez et al., 
2015). 
Action. The action stage is typically overt and observable, and elements of change are 
evident as individuals have taken concrete actions (Velasquez et al., 2015). For example, a 
smoker will have stopped smoking, or someone desiring to lose weight will have begun 
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exercising. This is both the busiest and hardest stage for individuals. They must remain focused 
to keep from regressing or returning to an earlier stage. According to Prochaska and DiClemente 
(1984), individuals who are the most successful at making a change work the hardest in the 
action stage for approximately six months, which they believe represents the steepest part of 
relapse curves across addictions. Accordingly, the action stage is defined as having engagements 
in the new behavior for at least 6 months (Prochaska, 2013; Prochaska & DiClemente, 1982; 
Prochaska & Velicer, 1997; Velasquez et al., 2015). 
Maintenance. This stage is described as the point at which  people have completed the 
action stage and have sustained the desired behavior change. . It is expected that during this stage 
individuals will not feel the work is as difficult, but they will need to be prepared to cope with 
the continual possibility of relapse. Possible causes of relapse include intense feelings of anxiety, 
depression, loneliness, boredom, or stress, and these feelings can often trigger unhealthy coping 
mechanisms contributing to a relapse (Prochaska, 2013; Prochaska & DiClemente, 1982; 
Prochaska & Velicer, 1997; Velasquez et al., 2015). 
Termination. This stage is achieved when an individual no longer experiences significant 
temptations to relapse and is confident they will never return to their previous behavior. Ideally, 
the individual will have adopted new healthy behaviors that have become automatic. At this 
point, change efforts may be channeled into enhancing other aspects of the individual’s life. 
However, this stage of change is not always achieved and many individuals will remain in the 
maintenance stage, perhaps for their entire lifetime (Prochaska, 2013; Prochaska & DiClemente, 
1982; Prochaska & Velicer, 1997). 
Processes of Change. Processes of change are the covert and overt activities that people 
use to progress through the stages of change (Prochaska & Velicer, 1997) and act as a driving 
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force inducing behavior change (Velasquez, Crouch, Stephens, & DiClemente, 2015). According 
to the TTM, most individuals who effectively enact a behavior change use multiple change 
processes, whether attempting to change with or without therapy (DiClemente & Prochaska 
1982; Velasquez et al., 2015). In 1988, Prochaska, Velicer, DiClemente, and Fava demonstrated 
that a large degree of change could be attributed to 10 statistically separate processes of change 
described as experiential (thought oriented) or behavioral (action oriented) processes. The 
experiential processes include 1) consciousness raising, 2) dramatic relief, 3) self-reevaluation, 
4) environmental reevaluation, and 5) self-liberation. The behavioral processes are: 1) social 
liberation, 2) counterconditioning, 3) stimulus control, 4) contingency management (also referred 
to as reinforcement management), and 5) helping relationships (Prochaska & Velicer, 1997). 
Each of these change processes and their associations with the stages of change, are further 














The Experiential and Behavioral Processes of Change and Their Associated Stage of Change  
Stages of Change Experiential Processes (generally used in early stages of change) 
Precontemplation/Contemplation Consciousness Raising  Increasing awareness of the need to 
change  
Dramatic Relief The strong reaction of individuals who 




Reappraisal of the impact of the behavior 
on the environment or others 
Contemplation Self-Reevaluation Reexamination of the behavior and how 
it affects his or her life 
Social Liberation Noticing how changes in society and 
environment make it easier to change the 
behavior; noting how the behavior is 
viewed by general society and how 
society encourages healthier options 
 Behavioral Processes (generally used in later stages of change) 
Preparation Self-Liberation The belief that one can change and 
committing to make a change 
Action/Maintenance Stimulus Control Making changes in one’s environment to 
support behavior change 
Counter Conditioning Substituting new behaviors for the 





Rewarding oneself for not engaging in 
the target behavior 
Helping Relationships  Identifying relationships in one’s life 
that are supportive of the behavior 
change 
Sources: Prochaska & Velicer, 1997; Velasquez, Crouch, Stephens, & DiClemente, 2015; 
Velicer, Prochaska, Fava, Norman, & Redding, 1998 
 
Decisional Balance. Decisional Balance (DB), reflects the process by which individuals 
weigh the pros and cons of engaging in change. Decisional conflict between the pros and cons 
can often lead to profound ambivalence, which can result in a lack of change. However, in cases 
where an individual already perceives more cons for change compared to pros for change, 
increasing ambivalence can actually facilitate change. In either case, for change to occur 
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individuals must assign more value to the pros than the cons of change. As individuals identify 
more pros than cons they will advance from precontemplation into each of the other stages of 
change (Velasquez et al., 2015).   
Self-Efficacy (also referred to as Confidence). Self-efficacy, which was integrated from 
Bandura’s self-efficacy theory (Bandura, 1977), is the situation-specific confidence people have 
that they can cope with high risk situations without relapsing to their unhealthy or high-risk 
habit. This construct commonly is low in initial stages of change and increases in later stages. 
Temptation. Temptation reflects the intensity of urges to engage in a specific habit when 
in the midst of difficult situations. Prochaska and Velicer (1997) state that efficacy to cope with 
high-risk situations protects against relapsing in those situations (e.g., using a substance). They 
indicate that early research has identified up to 16 high-risk categories of relapse-determinants 
that occur in intrapersonal and interpersonal situations. Although the number of characteristics 
that distinguish the different clusters varies from study to study, most reported relapses fell into 
three categories: negative emotional states, interpersonal conflict, and social pressure. The model 
speculates that the probability of relapse will decline as an individual’s ability to cope with high-
risk situations increases (Prochaska & Velicer, 1997; Velicer, DiClemente, & Prochaska, 1990).  
Key Concepts and Terms 
Specific diagnostic criteria for SUD and AD in this dissertation are based on the 
Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision (DSM)-IV-
TR (American Psychiatric Association [APA], 2000). Although the DSM-5 replaced the DSM-
IV-TR in 2015, the majority of the literature cited in this dissertation occurred prior to this 
transition. Changes to the DSM-5 include different terminology for mental and substance use 
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disorders (i.e., substance use disorder has replaced substance abuse and dependence) and 
qualifying criteria (e.g., symptoms).  
Changes in criteria for anxiety disorders were generally minor from the DSM-IV-TR to 
the DSM-5. Specific differences between the two diagnostic manuals that are directly relevant to 
this dissertation are reviewed in the following chapters. It is impractical to discuss others in 
detail here. A detailed list of these changes is available through PsychCentral and can be viewed 





SUBSTANCE MISUSE AND DISORDERS 
Substance (alcohol and other drug) jargon has steadily evolved from the broad terms of 
consumption, abuse, dependence, and addiction, to more specific phrasing such as chemical 
abuse/dependence, and finally to explicit terms for each type of substance (e.g., alcohol 
abuse/dependence, cocaine abuse/dependence). The most commonly used distinctions among 
substance use behaviors come from the DSM-IV-TR, which employs the terms substance use, 
misuse, abuse, and dependence (APA, 2001). Each term warrants further discussion.  
Substance Misuse. Substance misuse indicates use outside of recommended 
guidelines. For instance, in the case of alcohol use, it refers to drinking behavior that exceeds 
recommended drinking limits. These behaviors are often referred to as hazardous, binge, and 
heavy drinking (NIAAA, 2000; Reid, Fiellin, & O’Connor, 1999). By this definition, drug 
misuse is any use beyond recommended guidelines, which in the case of illicit drugs is zero.  
However, the definition of using a substance beyond recommended guidelines (limits) 
can be somewhat nebulous and is often contested. For instance, in the United States, the 
Substance Abuse and Mental Health Services Administration (SAMHSA, 2011) describes binge 
drinking as drinking five or more drinks within a couple hours of each other on at least one day a 
month. However, in the United Kingdom, binge drinking is more vaguely described as too much 
alcohol over a short period of time, e.g., over the course of an evening, and is typically drinking 
that leads to drunkenness (Department of Health for Culture, Media and Sport, 2007).  
SUBSTANCE ABUSE. As with substance misuse, there are several definitions  of substance 
abuse. The World Health Organization (2011) defines substance abuse as the harmful or 
hazardous use of psychoactive substances, including alcohol and illicit drugs, and the DSM IV-
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TR defines it as, “…a maladaptive pattern of substance use manifested by current and significant 
adverse consequences related to the repeated use of substances” (APA 2001, p. 198).  
In distinguishing between misuse and abuse, misuse may be defined as using a substance 
in a manner that causes a detrimental effect/s in some area of a person's life, while abuse is more 
specifically defined as the continued use of a substance despite the occurrence of significant 
detrimental effects (Stevens & Smith, 2013). The DSM-IV-TR identifies the areas in a person’s 
life where this could occur in terms of health, social (e.g., family), vocational, school, and/or 
economic difficulties (APA, 2001).  
SUBSTANCE DEPENDENCE. According to the DSM-IV-TR (APA, 2001), substance 
dependence is defined as “a maladaptive pattern of substance use leading to clinically significant 
impairment or distress” (p. 110). To meet diagnostic criteria for a dependence disorder, an 
individual must manifest three or more of the following within a 12-month period:  
1. Tolerance, as defined by either 
a. a need for markedly increased amounts of the substance to achieve intoxication  
b. markedly diminished effect with continued use of the same amount of the 
substance 
2. Withdrawal, as manifested by either  
a. The characteristic withdrawal syndrome for the substance 
b. The same (or a closely related) substance is taken to relieve or avoid withdrawal 
symptoms 
3. The substance is often taken in larger amounts or over a longer period of time than 
intended 
4. There is a persistent desire or unsuccessful efforts to cut down or control substance use 
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5. A great deal of time is spent in activities necessary to obtain the substance 
6. Important social, occupational, or recreational activities are given up or reduced because 
of substance use 
7. The substance use is continued despite knowledge of having a persistent or recurrent 
physical or psychological problem that is likely to have been caused or exacerbated by 
the substance  
Most recently, in the DSM 5 (APA, 2015) diagnoses of substance abuse and substance 
dependence have been consolidated under the single term, substance use disorder. Under this 
umbrella term, diagnoses include specifiers of mild, moderate, and severe and should be specific 
to the type of substance the individual is using, e.g.,. alcohol use disorder, severe. These terms as 
well as a description of their origins as defined by the World Health Organization (WHO), the 
American Psychiatric Association (APA), and the Substance Abuse and Mental Health Services 













Substance use definitions 
  
Term Definition Source DSM 
Version 
Substance Misuse Use of a substance for a purpose not consistent with 
legal or medical guidelines. 
WHO, 2006 NA 
Substance Abuse A maladaptive pattern of substance use leading to 







A cluster of physiological, behavioral and cognitive 
phenomena in which the use of a substance or a class 
of substances takes on a much higher priority for a 
given individual than other behaviors that once had 
greater value. A central descriptive characteristic of 
the dependence syndrome is the desire (often strong, 
sometimes overpowering) to take psychoactive drugs 
(which may or may not have been medically 





Substance use disorders occur when the recurrent use 
of alcohol and/or drugs causes clinically significant 
impairment, including health problems, disability, and 






While each of the above definitions is relevant to the discussion of substance use, using 
so many terms in this dissertation would be impractical. Therefore, the term substance use 
disorder (SUD) is used to describe substance use behavior that meets thresholds for diagnostic 
criteria in the DSM IV (including abuse and dependence) or DSM 5, while substance misuse will 
be reserved for describing behaviors that do not meet diagnostic thresholds, such as binge or 
heavy drinking. The choice to use the terms substance use disorder (SUD) and substance misuse 
does not imply that other terms do not have validity; it is merely a way to apply terminology and 
meanings consistently throughout the text.  
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Another topic that requires discussion is the specification of  the types of substances 
discussed in this dissertation. Here, the reader should be aware of the differences between the 
terms substances, drugs, illicit drugs, and alcohol.  
SUBSTANCE VS DRUG. There can be  confusion between the terms substances and drugs, 
which are often used interchangeably in the literature. While the term “substance” broadly 
includes all drugs and other sources of harmful elements such as alcohol, inhalants, solvents, and 
naturally occurring plants (McNeece & DiNitto, 2012), it is still necessary to distinguish a drug 
from other substances. Part of the confusion lies in the fluidity of the definition of drug, which 
constantly shifts due to changes in the law, differences in cultures, and overall classification of 
substances such as foods, poisons, beverages, medicines, and herbs (Stevens & Smith, 2013).  
Stevens and Smith (2013) define a drug as, “any nonfood substance whose chemical or 
physical nature significantly alters structure, function, or perception (vision, taste, hearing, touch, 
and smell) in the living organism” (p. 18). In this sense, the legality of a substance does not 
determine whether it is defined as a drug. For instance, alcohol, nicotine, and caffeine can be 
obtained legally but are considered drugs in the same way as illicit drugs such as marijuana. 
 In accordance with this definition, the focus of unhealthy behavior is placed on the user, 
rather than on the substance. For instance, a drug user or substance abuser is a person who 
intentionally takes legal or illegal drugs to alter his or her functioning or state of consciousness. 
In effect, any psychoactive substance, whether legal or illegal, can be abused. Of course, while 
drugs can refer to countless substances fitting the above description, they generally refer to illicit 
substances and non-medically used prescription medication (NSDUH, 2015). This dissertation 
focuses on three specific categories of substances: alcohol (which adults can obtain legally), 
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marijuana (which can be obtained legally in some states for medical and/or recreational 
purposes), and illicit drugs (which cannot be obtained legally anywhere in the United States). 
Categories of Substances & Epidemiology 
There is no shortage of articles describing the effects of substance use throughout history. 
In fact, a search of the terms ‘substance use, substance abuse, and substance misuse’ produced 
249,000 articles with 23,900 of them having been published in the past 10 years. Findings from 
this volume of literature show that substance use and related problems are not confined to any 
single demographic and can affect people of any age, sex, race, ethnicity, religion, 
socioeconomic status, and geography (Rippeth, 2008). Furthermore, the negative impacts of 
substances are far reaching and include mental, physical, and sociological concerns. 
One issue that is sure to plague readers concerns the natural origin of substance 
abuse/dependence. For instance, one might question whether it is a disease of the body, a bad 
habit, or simply a moral turpitude (McNeece & DiNitto, 2012). Among these possibilities, 
theorists have attributed substance abuse causes to genetics, culture, and even the devil. 
Unfortunately, as this question has persisted through decades of research without any clear 
answer, no answer can be divined in this text. Rather, the paper explores a variety of possible 
correlates of abuse and dependence for each specified substance category. 
ALCOHOL. Alcohol, which can be considered both a substance and a drug, belongs to a 
class of chemicals called central nervous system (CNS) depressants. More specifically, it is a 
chemical compound that when ingested has the pharmacological property of altering the 
functioning of the central nervous system (McNeece & DiNitto, 2012). Although there are 
several types of alcohol, ethyl alcohol or ethanol is the type meant for human consumption. 
These beverages generally contain ethyl alcohol (C2H2OH), congeners, (by-products of 
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fermentation), colorings, flavorings, and water (Levin, 1989). According to the Centers for 
Disease Control and Prevention (CDC, 2017), one standard drink is equal to 14.0 grams (0.6 
ounces) of pure alcohol. Generally, this amount of pure alcohol is found in: 
• 12-ounces of beer (5% alcohol content) 
• 8-ounces of malt liquor (7% alcohol content) 
• 5-ounces of wine (12% alcohol content) 
• 1.5-ounces or a “shot” of 80-proof (40% alcohol content) distilled spirits or liquor (e.g., 
gin, rum, vodka, whiskey) 
 
The production, distribution, sale, and use of alcohol is regulated throughout the world, 
and more heavily in the United States than in Europe (particularly in regard to age restrictions). 
With its allure of pleasurable promises, especially as advertised by the alcohol industry, it is 
widely used. For instance, in 2012 the World Health Organization (WHO) published estimates of 
alcohol consumption of those age 15-years and older. From 2003 to 2005, the average annual 
consumption of pure alcohol in the United States was almost 2.5 gallons per capita.  
Unfortunately, a fair amount of this drinking falls into the categories beyond the 
recommended drinking limits. In 2016, the Substance Abuse and Mental Health Administration 
(SAMHSA) observed that of the 138.2 million current alcohol users in the US, nearly half 
(48.2%) reported binge alcohol use (5 or more drinks within a couple of hours of each other, at 
least one day a month) with approximately, 5.8% (1.4 million) of these falling between the ages 
of 12-17, and 39% (13.6 million) between the ages of 18-25 (SAMHSA, 2016).  
Although plenty of literature indicates that any alcohol consumption comes with some 
risk, those who engage in excessive consumption face significantly greater negative 
consequences. For instance, the WHO (2012) has identified alcohol as a causal factor in 60 types 
of diseases and injuries and a component cause in 200 others. The WHO further identifies that 
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alcohol accounts for 4% of all fatalities world-wide, which is more than are caused by 
HIV/AIDS or tuberculosis, and is the leading risk factor for death among males aged 15-59.  
Beyond the physical risks associated with excessive drinking are the social issues. These 
include traffic accidents (drinking while under the influence and ‘road rage’), violence, child 
neglect and abuse, and work place absenteeism. Additionally, an array of risk factors are 
associated with alcohol use, particularly in young people, such as smoking, illegal drug use, risky 
sexual behavior, disruptive behavior, depression, anxiety, eating disorders and obesity, and 
suicidal and homicidal behaviors (Newbury-Birch et al., 2009).  
ILLICIT DRUGS. Illicit drugs are any type of drug prohibited by law and include CNS 
depressants, stimulants, opiates, and hallucinogens. As each is further explained, the reader will 
undoubtedly observe that some drugs listed below are not explicitly illicit, however, these drugs 
may become illicit through misuse or abuse.  
The following definitions are as cited from McNeece & DiNitto (2012). The first 
classification is Central Nervous System (CNS) depressants, which are commonly referred to as 
sedative-hypnotics. These drugs are often used medically in the induction of anesthesia and the 
reduction of anxiety. Alcohol is a CNS depressant. The most commonly known illicit drug 
within the CNS category is cannabis (marijuana). However, because of the complex nature and 
magnitude of its influence, cannabis will be discussed separately from other illicit drugs. Opiates 
are substances such as heroine, morphine, codeine, opioids, and synthetic morphine-like 
substances (pethidine, methadone, dipipanone). Small doses will produce an effect similar to that 
of the CNS depressants, but with somewhat less impairment of the motor and intellectual process 
(dug text, 2001). The next category, CNS stimulants, are drugs that in small doses produce an 
increased sense of alertness and energy, elevated mood, and decreased appetite but can be fatal 
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in large doses. Common to this group are cocaine, amphetamines, methamphetamines, and 
amphetamine-like substances (Ritalin and Preludin).  
Finally, hallucinogens have the capacity to induce altered perceptions, thoughts, and 
feelings. Some common types of hallucinogens include Lysergic acid diethylamide (LSD), 
mescaline, and “magic mushrooms” (which contain the ingredient psilocybin). Furthermore, 
volatile solvents (gasoline, benzene, and trichlorethylene), can also produce effects similar to 
CNS depressants and hallucinogens when their vapor is inhaled (McNeece & DiNitto, 2012).  
Illicit drug use trends in the US show a dramatic increase in the last decade. In 2007, 
approximately 8% (20 million) of Americans used illicit drugs in 30 days prior to the survey 
(SAMHSA, 2008) compared to roughly 10% (27 million) in 2015 (SAMHSA, 2016). Of those 
who reported illicit drug use in the 2015 survey, the majority reported using either marijuana or 
another illicit drug along with marijuana. The remainder, about 6.9 million users, reported using 
psychotherapeutics non-medically, including pain relievers (3.8 million), cocaine (1.9 million), 
tranquilizers (1.9 million), stimulants (1.7 million), and sedatives (.4 million). However, no 
single category of drug accounts for the increase of overall rates of drug use as all categories of 
drug use were up from 2007. 
It is well known that illegal drug use can negatively impact an individual and even groups 
of individuals as it confers a substantial burden on families, social networks, and society as a 
whole through violent and property crime, incarceration, poverty, and homelessness. Although 
illicit drug use in itself has demonstrated negative effects, those who develop drug use disorders 
(DUDs) are at increased risk. For this group, illicit drug use is positively associated with 
significant impairment in major life roles and increased risk for neuropsychological deficits, 
diminished quality of life, and infectious diseases (Grant, Saha, & Ruan, 2016).  
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Additionally, those that engage in illicit drug use increase their chances of experiencing 
or causing physical harm (Eaton et al., 2013). In a nationally representative 20-year follow up 
study, it was observed that drug users suffered increased risk for suicide, poisoning, homicide, 
unintentional injury, and over-all increased mortality rates, which were considerably increased 
for heroin and cocaine users (Walker, Pratt, & Druss, 2017). 
In summary, while alcohol misuse and disorders are more prevalent, i.e., they impact a 
greater number of individuals, the actual consequences of alcohol abuse and illicit substance use 
are similar to each other. However, illicit drug users also face other increased risks, including 
HIV/AIDS, hepatitis, and criminal behavior related to the acquisition and sale of illicit drugs in 
addition to a wide range of other risk behaviors (Stevens & Smith, 2013). Ultimately, illegal drug 
use makes users vulnerable to substantially greater rates of long-term disability and excess 
mortality (Degenhardt et al., 2013; Whitford et al., 2013). 
MARIJUANA. Cannabis, or marijuana, which is also known as Indian-hemp, hash, pot, 
herb, weed, grass, widow, ganja, or dope, is the most commonly used illicit drug (McNeece & 
DiNitto, 2012). Cannabis refers to the plant belonging to the family Cannabaceae, the genus 
Cannabis, and the species Cannabis sativa, and possess psychoactive effects. More than 70 
psychoactive compounds called “cannabinoids” have been identified in cannabis, among which 
tetrahydrocannabinol (THC) accounts for most of the psychological and physical effects, and its 
content is often used as a measure of sample potency (Leung, 2011). 
Although marijuana falls within the definition of an illicit drug (as described above), it is 
referred to separately here for two reasons. The first is owing to the new and seemingly ever-
changing fabric of cannabis laws in the United States. Under federal law, marijuana is still 
federally considered a Schedule I substance, meaning that is not recognized as having any 
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medical use; however, as of 2016, 26 states have legalized marijuana use for medical and/or 
recreational purposes (“State Marijuana Laws”, 2017).  
Though it is too soon to accurately measure effects on the population as a result of 
legalizing consumption for recreational use, we can see some of the effects of legalizing 
marijuana for medical use. For instance, O’Connell and Bou-Matar (2007) report that by 2007, in 
Washington state, up to 2,000 licensed physicians had begun prescribing medical cannabis, and 
at the same time, California, the first state to legalize medical marijuana use (in 1996), reported 
that 350,000 patients already possessed a physician’s recommendation to use cannabis 
(Ammerman et al., 2015). However, we do not know if this has been helpful or harmful to 
medical users. 
In part, marijuana’s growth in popularity comes from the growing public view that 
marijuana’s effects are relatively benign. However, ample literature suggests otherwise. Though 
no fatalities have been identified as solely attributable to a marijuana overdose, observed side 
effects of marijuana use include increased heart rate and systolic blood pressure, conjunctival 
injection, dry mouth, orthostatic hypotension, increased appetite, increased thirst, drowsiness, 
insomnia, anxiety symptoms, panic attacks, short-term memory loss, hallucinations, and ataxia 
(Wang, Collet, Shapiro, & Ware, 2008). Ingestion of marijuana by children can result in a variety 
of symptoms, including drowsiness, ataxia, nystagmus, hypothermia, and hypotonia (Wang, 
Roosevelt, & Heard, 2013). 
Another risk of marijuana use is the chance of developing a marijuana use disorder as 
well as increased risk of cross addiction to other substances, especially when use begins at early 
ages when the brain is still developing (Stevens & Smith, 2013). Research on adolescent brain 
development has found that brain maturation, particularly that of the prefrontal cortex, continues 
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into the mid-20s and can be negatively impacted through marijuana exposure (Sowell et al., 
2004). Further, it is suggested that the developing adolescent brain is particularly susceptible to 
the negative effects of substance use, including the potential for developing substance use 
disorders, although a number of other factors may be involved, including genetic predisposition, 
environment, and mental health disorders (Giedd, 2004). Additionally , reports of increased 
lifetime marijuana use are positively correlated with overall lower cognitive functioning 
(Gonzalez & Swanson, 2012). 
Other concerns about marijuana use generally depend on the amount and chronicity of 
use as well as on how the drug is introduced to the body. For example, likely risks of smoking 
marijuana include lung disease and cancer, while all types of consumption are associated with a 
number of physical and psychological symptoms including depression and lethargy (Stevens and 
Smith, 2013). Though these studies may not end the debate about the significance of the dangers 
associated with marijuana use, they do highlight a serious potential for harm inherent to the drug.  
Another reason marijuana is discussed separately from (other) illicit drugs is in regard to 
the sub-population of the military discussed throughout this dissertation. Although many states 
have removed restrictions or enforcement of penalties for using, the military remains a staunch 
zero tolerance organization, and, as is the case with other illicit drug use, military members face 
serious consequences if they are caught using marijuana (LaKind, Sericano, & Still, 2013). In 
other words, while the Department of Veterans Affairs (VA) has issued a directive that permits 
veterans to use medical marijuana in states where it is legal without losing their medical benefits, 
military members remain barred from recreational marijuana use, regardless of whether or not 
the service member lives or is stationed in a state like California that has fully legalized 




Anxiety disorders, defined by excess worry, hyperarousal, and fear that is 
counterproductive and debilitating, are considered the most common form of psychiatric illness 
found among any age group (Simpson et al., 2010). The prevalence of anxiety disorders in the 
United States is estimated to be nearly 40 million, or 18% each year (Kessler et al., 2005), and 
their annual cost is reported to be $42.3 billion (Wittchen, 2002). Further, the Global Burden of 
Disease (GBD) study estimated that anxiety disorders contributed to a loss of 26.8 million years 
of full health in 2010 (Whiteford et al., 2013). 
One possible reason ADs are so prevalent is that anxiety is deeply associated with fear, 
which is something we all experience. However, the terms anxiety and fear are not the same. 
First, fear is an immediate and rapidly evolving emotional response to real or perceived 
imminent threats in the environment. Comparatively, anxiety is a more sustained, heightened 
state of apprehension in anticipation of future threats (Remes, Brayne, Vander Linde, & 
Lafortune, 2015). 
Stress is another term that, while subtly different, shares similarities with anxiety and fear 
and therefore requires discussion. According to Webster’s Third New International Dictionary 
(1981, p. 2260), stress is defined as “a physical, chemical, or emotional factor (as trauma 
histamine, or fear) to which an individual fails to make satisfactory adaptation and which causes 
physiologic tensions that may be a contributing cause of disease.” In this sense, stress can result 
from either fear or anxiety or it can be a contributing factor to fear or anxiety, making the 
distinctions and causal relationships fuzzy at best.  
Notably, while each of these terms have different meanings, they share similar 
symptomology including physiological arousal (increased heart rate), increased alertness, 
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increased motor reactivity, and potentially a fight-or-flight response. In truth, when it comes to a 
diagnosis, it may not be possible to completely isolate the terms. For instance, fear, stress, and 
anxiety can be experienced on a normal to abnormal spectrum, where the abnormal indicates a 
clinical diagnosis (Sylvester & Pine, 2016).  
In these cases, extreme types of fear can be diagnosed as phobias, while abnormal, 
chronic, or extreme cases of stress and anxiety result in a slew of anxiety disorders including 
adjustment disorders, Generalized Anxiety Disorder (GAD), Social Anxiety Disorders (SAD), 
panic disorders (PD) and Post-Traumatic Stress Disorder (PTSD), to name a few (Steel, 






Research and clinical experience commonly show that when anxiety and substance use 
disorders simultaneously occur, these disorders are functionally intertwined in both their 
development and maintenance (Smith & Book, 2008). However, the relationship between these 
diagnoses is made all the more difficult to comprehend through muddled clarity of key terms. 
For instance, while one study may refer to the interaction between anxiety and substance use 
disorders as a dual diagnosis, another might refer to the same relationship as co-occurring or 
comorbid. Therefore, before discussing this topic further, these terms need clarification.  
Comorbidity is used when describing two or more disorders or illnesses occurring 
simultaneously in the same person (Mizrahi & Davis, 2008). Comorbidity also implies 
interactions between the illnesses that can worsen the course of both (NIDA, 2010). Co-
occurrence may include any combination of two or more substance use disorders and/or mental 
disorders identified in the Diagnostic and Statistical Manual of Mental Disorders that occur at 
the same time. While the terms comorbidity and co-occurring are often used interchangeably, 
there is a subtle difference. Simply, when referring to two or more simultaneously occurring 
disorders in the same person, either term is appropriate. However, comorbidity is more apt when 
discussing an interaction between diagnoses, where one disorder, disease, or illness, is expected 
to impact the nature of another.  
Finally, dual diagnosis is the least commonly used term and is generally reserved for 
specific reference to individuals with both a clinically significant mental illness and a substance 
use disorder (Mueser et al., 2003). While these terms are likely to vary by field or practice, in the 
interest of simplification, for this dissertation, the term comorbidity will be used as a proxy for 




 The literature identifies a greater prevalence of substance users who report also 
experiencing anxiety, when compared to those diagnosed with a non-substance induced anxiety 
disorder who also report substance use problems (Wong, 2014). Data from the National 
Epidemiologic Survey on Alcohol and Related Conditions demonstrates these correlations citing 
that among respondents with a 12-month SUD, almost 18% also met criteria for a non-substance 
induced anxiety disorder, while about 15% of those who sought treatment for an anxiety disorder 
also met criteria for a SUD (Grant et al., 2004). A prominent feature of concern for those who 
endorse both substance use and anxiety disorders is how each seems to perpetuate the other 
(Wong, 2014).  Patients endorsing both substance use and anxiety disorders also endorse greater 
symptom severity and impairment than those who identify only one of these disorders (Bruce et 
al., 2005; Driessen et al., 2001; Ouimette, Ahrens, Moos, & Finney, 1997).  
Those patients with comorbid conditions also report worse treatment outcomes, report  a 
lower willingness to engage in treatment, poorer treatment adherence, and overall poorer 
recovery (Ouimette et al., 1997). For instance, in a 12-year prospective study (N=3018), Bruce et 
al. (2005) found that the co-occurrence of SUD decreased chances of generalized anxiety 
disorder (GAD) recovery more than threefold. Another study (N =100) showed that anxiety 
comorbidity was associated with increased alcohol use relapse even though treatment completion 
was 69% among these individuals compared to 40% for those diagnosed solely with a SUD. 
However, the extent of the relationship between anxiety disorders and SUD remains unclear 
owing to the small sample sizes of recent studies as well as the range in severity and complexity 
of each diagnosis (Driessen et al., 2001).  
26 
 
In an attempt to better describe how relationships between SUDs and ADs are developed 
and maintained, several hypotheses have been developed. Often referred to as primary pathways 
to comorbidity, Smith (2008) describes three proposed causal models that are continually cited in 
the literature: the self-medication model, the substance-induced anxiety model, and the common 
factor model (Smith & Book, 2008; Smith & Randall, 2012; Stewart & Conrod, 2008).  
The Self-Medication Model, an AD pathway to SUD, suggests individuals use drugs or 
alcohol to cope with psychological distress, which ultimately results in a comorbid SUD 
(Chilcoat & Breslau, 1998; Khantzian, 1985). In this situation, anxiety precedes the SUD, and 
this arrangement is the scenario most often borne out in research studies. As one example, 
analyses of the National Comorbidity Survey showed that 79.3% of those who exhibited a 
comorbid AD and SUD indicated their anxiety symptoms existed prior to their substance misuse 
(Kessler, Chiu, Demler, & Walters, 2005).  
However, a significant limitation of this hypothesized pathway persists. While the model 
may account for the development of comorbidity, it does not adequately account for the 
maintenance of co-occurrence that may be affected by neurobiological changes chronic 
substance users experience. In other words, the self-medication hypothesis may explain the 
development of SUD for some, but it does not explain the continued use and poor recovery rates 
from problematic substance use after psychological symptoms are reduced (Wong, 2014). 
 The Substance-Induced Anxiety Model, also known as the susceptibility hypothesis, posits 
that substance use can promote the development of an anxiety disorder (Chilcoat & Breslau, 
1998). In this model, the explanation for comorbidity is that anxiety is a consequence of heavy, 
prolonged substance use (Smith & Randall, 2012). This theory proposes that repeated substance 
use reduces the threshold for the development of psychological symptoms. Then, in what is 
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sometimes described as a ‘kindling process,’ a substance user experiences repeated withdrawal, 
which leads to a hyper-responsive central nervous system that is susceptible to heightened panic 
and anxiety.  
Additionally, withdrawal periods can induce changes in anxiety producing systems in the 
brain known as ‘hyperexcitability,’ which occurs through over-stimulation of the limbic and 
norepinephrine systems (Kushner et al., 2000; Marshall 1996), that are involved in producing 
panic attacks (Graeff & Del-Ben 2008; Marshall 1996). The user, in turn, increases substance use 
to cope with ever-increasing symptom severity (e.g., Kushner, Sher, & Beitman, 1990). 
 While the limitation of the self-medication model was that there were no noticeable 
reductions in substance use after treating anxiety, a similar statement may not be able to be made 
about the substance-induced anxiety model. In fact, this model specifically predicts that 
abstinence from alcohol should result in reduced anxiety symptoms, and data seems to support 
this hypothesis. For example, in a study of 53 residential substance abuse patients who 
participated in alcohol treatment, 69% of participants who reported no relapse at follow-up 
(approximately 127 days following initial treatment) subsequently reported decreased anxiety 
symptoms (Kushner, Abrams, Hanson, Brekke, & Sletten, 2005). This finding is supported in 
another study where 171 male veterans reported that anxiety symptoms decreased rapidly during 
inpatient alcohol treatment, and participants who reported experiencing a relapse also reported 
significantly higher rates of anxiety symptoms (Brown Irwin, & Schuckit, 1991). Despite these 
findings, few studies have examined this relationship. More research is needed before these 
findings can be applied more broadly.  
 Unlike the previous two models, the third model, the Common Factor Model, does not 
identify a direct causal relationship between the two disorders. Rather, it suggests that a third 
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variable accounts for the presence of both disorders. Although it is difficult to accurately account 
for a full range of common factors, the most consistently proposed third variables are genetic 
factors and personality traits such as anxiety sensitivity (Smith & Randall, 2012). 
Though family and twin studies support the role of genetic factors as a cause of these 
disorders (e.g., Merikangas Risch, & Weissman, 1994, 1996; Tambs, Harris, & Magnus, 1997), 
another common factor could be anxiety sensitivity. Specifically, anxiety sensitivity is a 
tendency to fear bodily sensations associated with the experience of anxiety, which is then 
interpreted as signs of an impending negative outcome (Reiss, Peterson, Gursky, & McNally, 
1986). In effect, it is hypothesized that anxiety sensitivity functions as a moderator where those 
with high anxiety sensitivity are more motivated to avoid anxiety sensations and to use 
substances as an avoidance strategy (Reiss, 1991). Additionally, those high in anxiety sensitivity 
may experience a more robust anxiolytic effect from substance use (Stewart & Pihl, 1994). 
Since the majority of literature on this model examines the effects of comorbid anxiety 
and alcohol use disorder, likely because it is much more common (Wong, 2014), it is unclear 
whether this particular model is applicable to other substance use disorders. Regardless, this 
model provides an interesting perspective on the cause and maintenance of comorbidity and 





MILITARY SUB POPULATION 
While SUDs, AUDs, and comorbidity between the two are clearly significant concerns 
facing the general population, some groups face even greater risk of developing these disorders. 
One such group is the military, which has been identified as having increased rates of SUDs, 
ADs, and co-morbidity (Bray et al., 2010). Because military members are recruited directly from 
the civilian population, it would seem logical that the two groups would share similar 
demographics. However, several distinct differences between the general civilian population and 
military members must be considered.  
Notably, the military is comprised of a larger percentage of younger males than the 
civilian population (Bray, 1991). Additionally, military members often experience different life 
stressors than civilians, including deployment, overseas assignments, separation from family, and 
more constant oversight and supervision (Bray, Marsden, & Peterson, 1991; Lazar, 2014; 
Maguen, et al., 2012). Finally, the military may attract people with particular personality traits. 
For example, a study sponsored by the U.S. Army described a distinct difference in military 
members through its appeal to individuals who possess attributes such as “sensation-seeking, 
impulsivity, and physical aggressiveness” (Rosellini et al., 2015, p. 18).  
Due to the military’s unique environment and characteristics, its members may face even 
greater risks for SUD, AD, and comorbidity than the civilian population. As a result, this group 
provides unique opportunities to examine SUDs, ADs, and comorbidity, which will hopefully 
yield clearer findings for future prevention and/or treatment. For these reasons, the military sub-
population will be examined separately from the generally civilian population in regard to both 
SA and anxiety.  
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Substance Abuse and the Military 
Researchers have already identified greater prevalence of substance abuse in military 
members compared to civilians, especially in regard to alcohol use (MHAT, 2006). For instance, 
a study conducted in 1991 found prevalence of any drinking among all military personnel was 
about 8 to10 percentage points higher than that of civilians (Bray, 1991).  A later trend study on 
this group of personnel showed heavy drinking increased significantly from 1998 to 2008 (Bray, 
2010). The distinct conditions of military life, including living overseas, separation from family, 
and a greater perceived acceptance of alcohol use, may engender a unique military perspective 
with regard to substance use (Bray, 2010).  
Another factor for increased substance use among military members is a military 
member’s involvement in combat operations, which provides significant potential for traumatic 
experiences most civilians will never face (Moore et al., 2009). The military attempts to counter 
this increased risk for substance abuse and dependence through substance abuse prevention, 
identification, and treatment programs (Larson et al., 2012). A zero-tolerance policy has been 
enacted as an initial deterrence against illicit drug use (DOD, 2014).  
Though a wide variety of treatment options are made available to military members, 
Larson et al. (2012), describe reasons members may conceal developing substance use disorders, 
including the warrior ethos, referring to the idea that military members may view help-seeking 
behavior as a sign of weakness. They neither want to admit they need help, nor want to fall into a 
stigmatized category of the “sick” (Larson, 2012). While the military’s zero-tolerance illicit drug 
policy paired with frequent drug testing seem to effectively combat illicit drug use, which has 
dropped to a level comparable to civilian use, prescription drug and alcohol misuse has 
continued to rise, despite availability of military substance abuse programs (Bray, 2010).  
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While many theories have been offered to describe the onset and maintenance of SUDs in 
the military, no single theory is dominant. Researchers and clinicians continue to explore 
additional factors such as genetic components, personality traits, behavior, and disease and 
dependency models in an effort to better understand the nature of substance abuse in this 
population (Bray, Marsden, & Peterson, 1991; Bray et al., 2010; Bray, Spira, & Lane, 2011; 
Tsuang et al., 1996). For detailed comparison of these theories, see Lettieri and colleagues’ 
(1980) book, Theories on Drug Abuse: Selected Contemporary Perspectives.  
Anxiety and the Military 
Military members are also at higher risk of developing ADs than the general populace, 
with prevalence rates of ADs among military members significantly higher than for civilians. 
ADs affect an estimated 40 million adults in the general population or about 18% of the US 
population each year (Kessler, Chiu, Demler, & Walters, 2005; National Institute of Mental 
Health, 2009) and account for nearly 30% of treatment seeking patients primary care physicians 
see (Maxmen & Ward, 1995). In a study of the military population’s current mental health needs, 
Lazar (2014) identified that military members experience “internalizing disorders” such as 
anxiety at a rate 10% higher than civilians. In other words, military members likely face the same 
risk factors for developing ADs as the civilian population but also have additional risk factors 
due to their unique work environments. Some of these unique factors are high stress from 
demanding duties, frequent changes of duty and living locations, time spent away from family 
and loved ones, and exposure to traumatic events (Hoge, Auchterlonie & Milliken, 2006; 
Lovering, Proctor, & Heaton, 2013). Therefore, it is not surprising that military members have 
higher rates of ADs than civilians.  
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Beyond usual environmental risk factors, military members face increased susceptibility 
to SUDS, ADs, and comorbidity due to developmental, behavioral, and cognitive factors that are 
also unique to military members (Sirratt, Ozanian, & Traenkner, 2012). Though these differences 
may stem from basic personality traits such as those the US Army describes as sensation-
seeking, impulsivity, and physically aggressiveness (Rosellini et al., 2015), the underlying 
etiology of ADs among military members is likely to involve the interplay of biological and 
environmental factors and is likely to be complex. 
Co-occurrence of Disorders in the Military  
There is no denying the significant degree of co-morbidity among military members, 
especially regarding ADs and SUDs. As noted, prevalence rates for both SUDs and ADs are 
greater than the general population, which may also indicate the likelihood of a higher rate of co-
occurring ADs and SUDs. Unfortunately, it is difficult to identify the prevalence rates of co-
morbid ADs and SUDs for military members as most military studies examine multiple mental 
disorders (e.g. depression, PTSD, and suicidality) without specifically focusing on anxiety and 
substance use comorbidity.  
Given the lack of studies on these comorbid conditions, one may question whether it is 
important to examine co-morbid ADs and SUDs separate from other mental disorders. Williams 
et al. (2010) sheds light on this question in a study examining the differences between 
motivations to drink for those with depression compared to those with anxiety. He found that 
those with depression were distinctly different in their motivations to use alcohol than those with 
anxiety.  
Ultimately, the literature that does exist consistently suggests that there is a higher 
prevalence of alcohol use disorder and anxiety disorder comorbid relationships among the 
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military compared to civilians. For instance, two separate studies reporting rates of AD and SUD  
comorbidity ranged from 33% in the general military population to over 65% for those military 
members seeking treatment for these comorbid disorders (Burns, Teesson, & O’Neill, 2005; 
Haver & Dahlgren, 1995). 
Of all of the possible causal models, the self-medication model is the most often cited 
when discussing the relationships between anxiety and substance use among military members. 
However, it should be noted that most studies that explore these comorbid relationships focus 
primarily on PTSD and SUDs. In reviewing the studies that explore the relationship between 
PTSD and SUDs, common explanations are that military members are likely to experience 
greater exposure to trauma, which in-turn results in negative coping strategies.  
Following the self-medication model, exposure to traumatic events heightens risk for 
SUDs. This relationship is then mediated by the occurrence of PTSD or other posttraumatic 
psychiatric disorders (Jacobsen, Southwick, & Kosten, 2001; Khantzian, 1999). However, given 
that research pertaining to the self-medication model concerning these comorbid disorders 
among the military is limited to PTSD and SUDs, this is a significant gap in the literature. 
In further support of the self-medication model, learning-theory has also been used to 
explain the relationship between SUDs and ADs. In this theory, alcohol use is hypothesized to be 
negatively reinforcing, providing immediate and short-term relief from PTSD or other anxiety 
symptoms. For example, military veterans diagnosed with PTSD often report using alcohol and 
other drugs as a coping strategy to avoid symptoms of re-experiencing and hyperarousal 
(Douglas, Southwick, & Charney, 1996).  Given alcohol’s powerful, short-term negative 
reinforcement effects, it is easy to see how these individuals would fall into a pattern of frequent 




II. THEORY & TREATMENT OF CO-OCCURRING DISORDERS  
 The treatment of comorbid ADs and SUDs is a pressing concern for modern treatment 
providers given the disorders’ high prevalence and persistence. Although identifying “the best” 
treatment approach is beyond the scope of this dissertation, it is useful for the reader to have a 
basic understanding of current treatment models in these co-occurring disorders.  
The temporal ordering of treatment has garnered particular attention. Three main 
categories of treatment orders most often used to treat co-morbid disorders are: 1) sequential 
(treatment of one disorder is followed by treatment of the second comorbid disorder); 2) parallel 
(also referred to as concurrent or simultaneous, in which both comorbid disorders are treated at 
the same time, but not necessarily by the same provider or in the same treatment facility); and, 3) 
integrated treatment (both disorders are treated, or at least monitored simultaneously, by a single 
qualified provider) (Kavanagh & Connolly, 2009).  
Sequential Treatment  
Historically, sequential treatment has been the most common approach. Treatment 
centers, which often specialize in specific disorders, focus on one disorder and then follow up 
with a referral to another treatment program  to address the other comorbid disorder (Donald, 
Dower, & Kavanagh, 2005). In addition to being the most common approach, Kavanagh and 
Connolly (2009) make the case that the sequential model is also the most effective approach, 
particularly in cases where one disorder is clear primary and other is secondary. In this case, it is 
relatively easy to prioritize which treatment should come first. Moreover, this treatment model 
allows for the possibility that treating the primary disorder may significantly reduce the need for 
additional treatment of the secondary disorder.  
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There is also justification for treating one disorder first, even if it is not the primary 
disorder. For instance, typically in comorbid AD and SUD cases, the SUD is treated first, 
regardless of whether it is the primary disorder or not. Reasons for this are best described in a 
study by Back, Waldrop, and Brady (2009), where clinicians were surveyed about their attitudes 
about comorbid treatment. The authors found that a primary concern among clinicians was that 
exposing patients to traumatic memories, which often occurs through exposure therapy 
(particularly in treating PTSD), before treating the patients’ SUD exacerbated their substance use 
or resulted in a relapse. Also, when a person’s thinking is impaired by drug or alcohol use, it is 
difficult to benefit from therapy.  
Though there may be many benefits of this approach, there are also limitations. For 
instance, a primary limitation is that it could fail to adequately address the complex interactions 
between the two disorders. While treating SUDs first may seem logical, it may also prove to be a 
futile effort if anxiety concerns are not addressed. For example, even when healthy coping 
mechanisms are taught in SUD treatment, anxious feelings, self-doubt, and unwelcome recurrent 
thoughts may continue to drive unhealthy coping strategies, such as self-medication via drug or 
alcohol use (Stewart & Conrod, 2008).   
Parallel Treatment  
In the parallel treatment approach, both disorders are treated at the same time but by two 
different treatment providers or teams, one for each disorder. This addresses some of the earlier 
stated limitations of sequential treatment. However, without continued communication and 
coordination between treatment providers or teams, the parallel approach could suffer from the 
same limitations of treating each disorder as discrete and separate. Another concern is that 
treatment providers may follow different policies, protocols, and theoretical approaches and may 
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not communicate their strategies and concerns with the other provider (Donald et al., 2005). As a 
result, clients may receive conflicting messages from providers rather than coordinated care. 
Integrated Treatment 
In this third model, a patient either receives treatment for both disorders concurrently by 
the same treatment provider/team, or receives treatment from two providers/teams with one 
provider/team continually monitoring treatment for both disorders. Integrated treatment may not 
mean simultaneous treatment of both disorders; rather, it entails tailoring treatment techniques to 
address prevalent concerns, which typically change over the course of treatment (Kavanagh & 
Connolly, 2009). 
While integrated treatment may seem to be the most advantageous approach of the three 
types, there may be some drawbacks. The greatest challenge is that not all treatment providers 
are competent to treat or even monitor both disorders. For example, a treatment provider may be 
experienced in treating SUDs, but may lack knowledge or experience in treating significant 
trauma histories that patients with PTSD may have. Furthermore, it may be difficult to provide 
integrated treatments in many treatment facilities because they tend to specialize in treating a 
disorder such as AD but may not be equipped to address SUDs including detoxification, 
withdrawal, and relapse (Randall, Book, Carrigan, & Thomas, 2008).  
Little research has been conducted comparing sequential, parallel, and integrated 
treatment approaches. Donald and colleagues (2005) identified this dearth of literature in their 
review of randomized clinical trials comparing the three strategies. They identified only one 
study that compared a parallel treatment model to an integrated model, the results of which 
suggested little difference in overall outcomes. The authors noted that patients in the integrated 
treatment group had higher treatment participation rates, which is particularly significant for co-
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morbid AD and SUD treatment as low treatment participation is evident in both (Hellerstein, 
Rosenthal, & Miner, 1995). Donald et al. (2005), also noted that more research is needed before 
conclusions can be drawn. 
There is a general consensus that, given the safety concerns associated with 
detoxification and acute withdrawal, acute SUDs should be addressed before other treatment is 
introduced (Goldstein, Diamantouros, Schaffer, & Naranjo, 2006). However, there is no 
consensus on the ideal amount of time to wait after acute SUD treatment has been initiated 
before implementing anxiety treatment. In sum, research has yet to conclusively identify wheter 
any of the three strategies is more effective. Therefore, treating providers are left to determine 
the course of treatment on a case by case basis, considering the severity of disorders, presenting 
symptomology, availability of resources, and the patient’s preferences. This dissertation aims to 
help practitioners with these types of decisions by providing a description of the nature of 
anxiety’s role in substance use treatment outcomes.   
Anxiety and the Transtheoretical Model  
It has long been understood that a substantial barrier to behavior change is a client’s 
anxiety, either rendering an individual incapable of making the change, or instilling doubt that 
change will be effective (Cattell, 1966; Spielberger, 2013). This is also the case for substance 
abusers who may desire treatment but fear possible outcomes. Clinicians and researchers must 
therefore understand the nature of fear and anxiety on motivation and readiness to change.  
While no identified studies directly discuss anxiety and the transtheoretical model, 
research clearly articulates anxiety’s impact on motivation or readiness to change, particularly in 
studies that examined the effectiveness of Motivational Interviewing (MI) as a treatment 
approach. For instance, Westra, Arkowitz, and Dozois (2009), conducted an initial controlled test 
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of whether adding an MI pretreatment to CBT for GAD would enhance treatment outcomes. The 
sample was 76 clients with a principal diagnosis of GAD. One group received a brief MI 
pretreatment followed by CBT (MI-CBT) and the other group received no pretreatment (NPT), 
followed by a 4-week wait, and then by CBT (NPT-CBT). Results showed significant group 
differences in GAD symptom reduction favoring the MI-CBT group. The authors concluded that 
adding MI pretreatment to CBT was  beneficial in treating GAD for individuals with high worry 
severity at baseline.  
Overall, there is a clear link between anxiety and SUD treatment where anxiety acts as a 
barrier to engagement or completion of SUD treatment. While little research has directly related 
anxiety to TTM outcomes, some studies show that SUD treatment outcomes are significantly tied 
to TTM variables. For example, participants’ treatment outcomes could be predicted by their 
TTM scores, such as endorsements of pros versus cons (Carbonari & DiClemente 2000; von 
Sternberg, Velasquez, & DiClemente, 2012). As literature in this area is extremely limited, more 




III. GAPS IN THE LITERATURE 
This literature review reveals a strong association between AD and SUDs and that each 
disorder can negatively impact the other (Kushner, Krueger, Frye, & Peterson, 2008; Kushner, 
Sher, & Beitman, 1990). Yet, there is still much debate concerning the ways these disorders 
interact and how each disorder impacts the treatment outcomes for the other disorder. 
Researchers should examine the nature of anxiety’s impact on substance use outcomes and 
investigate how the change process differs for people with anxiety compared to those without.  
Taylor, Abramowitz, and McKay (2012) at least partially answered these questions in 
their review of recent literature on anxiety treatment. This review confirmed that about a fifth of 
patients drop out prematurely and a third of treatment completers are classified as non-
responders. They go on to suggest that risk of premature dropout is associated with low treatment 
motivation (Taylor, Abramowitz, & McKay, 2010). This seems to indicate that a further 
understanding of the relationship between anxiety and motivation, or readiness to change, could 
further understanding of anxiety’s impact on substance use disorder treatment.   
Given that the literature suggests significant differences in substance use outcomes when 
anxiety is or is not present, we must ask where in the process of change anxiety has the most 
impact. For example, does anxiety impact how an individual weighs pros and cons of changing, 
or how an individual rates confidence or temptations in situations of substance use? To address 
these questions and advance understanding of the relationship between anxiety and SUDs, this 
dissertation focuses on anxiety’s impact on the change process in relation to substance use 
outcomes. Specifically, substance use outcomes and the change process were examined for each 
of the TTM variables (i.e., decisional balance [DB], pros and cons; processes of change [POC], 
experiential and behavioral; and self-efficacy [SE], confidence and temptation; & readiness to 
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change obtained from the University of Rhode Island Change Assessment [URICA]) comparing 
those who endorse anxiety to those who do not.  
This work may aid researchers and practitioners in understanding whether/how anxiety 
impacts substance abuse treatment outcomes as well as how the change process may differ for 
each group. It may also be helpful in describing the pathways to success (e.g. abstinence or 
reduced substance use) for those with anxiety compared to those without. Additionally, it will 
help in developing treatment methods that focus on the most influential TTM components to 
ensure the highest rate of success. It may also help to target TTM components that compensate 
for differences between the two groups. This knowledge will ensure future care is both efficient, 
by eliminating additional treatment options that may be unnecessary or even detrimental, and 




IV. CURRENT STUDY 
This dissertation utilized data gathered as part of a NIDA funded, single blind, 
randomized control trial named Traumatic Injury Prevention (TIP), conducted between 2010 and 
2015 (NIH-NIDA, R01 AA022924). This study will systematically examine anxiety’s overall 
impact on substance use outcomes as well as the overall process of changing substance use 
behaviors. Two groups will be compared: those who meet the threshold of having clinical 
anxiety symptoms based on the Brief Symptom Inventory (BSI) anxiety subscale cutoff score 
(above 62), and those who do not (a score of 62 or below). Differences in substance use 
outcomes between the two groups will be compared based on percent days abstinent (PDA). 
PDA is calculated as the number of days where none of the study identified substances were 
reported over the past 90 days. The groups will also be compared on their processes of change 
based on the transtheoretical model constructs.  
Research Questions, Hypotheses, and Proposed Analysis 
RESEARCH QUESTION 1. Does the presence of anxiety impact substance use (as 
measured by PDA)? Those with little to no anxiety (62 or less on the BSI anxiety subscale) will 
be compared to those with moderate to high anxiety (more than 62 on the BSI anxiety subscale) 
by examining the Percent Days Abstinent for both groups over time (dependent variables 
measured at baseline, three months, six months, and 12 months).  
Hypothesis 1a. The anxiety group will report fewer days abstinent at baseline, 3-, 6-, and 
12-months.  
Analysis. Preliminary group difference tests of percent days abstinent (Independent 
samples T-test), and General Linear Model (GLM) Repeated Measures analyses will be used to 
compare the groups at baseline, 3-, 6-, and 12-months. 
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RESEARCH QUESTION 2. Per the Transtheoretical model, does the process of changing 
substance use differ for the anxiety group compared to the non-anxiety group? 
Analysis will compare the process of change for those with anxiety to those who endorse 
little to no anxiety by examining the group’s relationships with TTM components (i.e., decisional 
balance, self-efficacy, experiential and behavioral processes of change, and readiness) and their 
overall profile shape of TTM variables in relation to substance use (cannabis and cocaine) at 
four different time points.  
  Hypothesis 2a. The two groups will differ in how they engage in each TTM construct at 
each assessment time point (baseline, 3-, 6-, and 12-month follow-ups). It is expected that the 
anxiety group will report less perceived importance of pros and greater perceived importance for 
cons for change; less confidence in their ability to change and greater temptations to return to 
substance use; less engagement in both experiential and behavioral processes of change; and will 
score lower on their overall readiness to change compared to the non-anxiety group.  
Analysis. A Profile Analysis will be used at the four time points to examine differences 
between the anxiety and non-anxiety group on each TTM constructs (i.e., DB, ASE, POC, and 
URICA).  
Hypothesis 2b. The two groups will differ on their trajectory (degree of change) on each 
TTM construct over time. Since this is an exploratory study and research has not clearly 
identified where these trajectories would differ, differences are not predicted here. 
Analysis. SPSS AMOS software will be used to examine and compare the rate of change 
on each TTM variable, DB, Processes of Change (experiential processes and the behavioral 
processes), and Self-Efficacy (confidence and temptation) between the two groups through SEM 
Latent Growth Curve (LGC) analysis. Through this procedure, each TTM construct will be 
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examined between the two anxiety groups across four different time points (baseline, 3-, 6-, and 




This dissertation employs data from project TIP (Traumatic Injury Prevention), which 
was developed as part of a grant funded by the National Institute on Drug Abuse (R01 DA 
026088).  Project TIP aimed to study the possible reduction of traumatic injury by assessing the 
effectiveness of substance abuse treatment using Brief Motivational Interviewing (BMI). TIP 
was a three-group, single-blind, randomized controlled trial conducted at University Medical 
Center Brackenridge in Austin, Texas from March 2010 through June 2015.  
Study Design and Treatment Intervention 
 Participants in the original project TIP study were randomly assigned to one of three 
groups: Brief Advice (BA), Brief Motivational Interviewing (BMI), or Brief Motivational 
Interviewing plus a booster (BMI+B). The BA group, or treatment as usual group, received an 
initial interview conducted by a study staff member, a recommendation to abstain from drug use, 
provision of educational material supporting that recommendation, referral to hospital or 
community treatment resources most likely to be beneficial to the patient, and information about 
relevant community healthcare agencies. The BMI group received a single 30-45 minute face-to-
face individual session, using Motivational Interviewing (MI) and assessment feedback, aimed at 
targeting the participant’s drug use behaviors.  Participants assigned to the BMI+B group 
received the same intervention as the BMI group but also received one booster call 
approximately 4 weeks following the BMI intervention from the same clinician who conducted 
their initial intervention.  BMI and BMI+B participants also received personalized feedback to 
collaboratively discuss the role drug use plays in their life. When patients reported being 
motivated to change their drug use, a change plan was developed.  
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All three interventions were fully manualized and audio-taped. MI training for counselors 
included workshops, didactic sessions, structured readings, role plays, and performance feedback 
and was monitored through weekly clinical supervision in both individual and group sessions.  
Interventions were conducted in either English or Spanish, depending on the participant’s 
preferred language.   
Sample 
Project TIP participants were identified and recruited using the hospital’s daily trauma 
registry, which is an electronic medical record of admitted trauma unit patients. To be eligible 
for the study, participants had to meet the following criteria: 18 years or older; presented to the 
hospital with a traumatic injury (e.g. a motor vehicle collision as driver, passenger, or pedestrian, 
or violence-related injuries including gunshot wounds, stab wounds, or other injuries related to 
assaults and falls); screened positive for drugs on a toxicology screen and/or gave a verbal 
positive of illegal drug use within 30 days prior to the traumatic injury for which they were being 
treated; and be available for the follow-up period. Exclusion criteria included the following: 
cognitive impairment; serious mental illness; high suicide risk; re-admittance for prior injury; 
insufficient contact information; living outside catchment area; inability to provide informed 
consent; and detected drug use due to medication taken as prescribed by a health professional 
(meaning the subject was falsely identified as using an illicit substance due to the effects of a 
prescribed drug on the screener).  
A total of 9,072 individuals were identified through the trauma registry during the 
recruitment period. Of these, 5,127 hospital patients were screened for participation and 777 of 
these individuals met study inclusion criteria. It should be noted, that 77 participants were 
funneled to another study called “MARIA”, which was a concurrent study being run by the same  
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that examined alcohol use. Ultimately, 416 patients were assigned to and agreed to participate in 
Project TIPS and provided written informed consent. The Institutional Review Boards at the 
University of Texas at Austin and University Medical Center Brackenridge approved study 
protocols and a Certificate of Confidentiality was obtained from NIH/NIDA (See figure 4.1 
below for recruitment details). 
 
Figure 4.1. Participant Flow Chart (obtained from Project TIPS manuscript in press) 
 
Of the original 416 participants that were identified as eligible and agreed to participate in 
this study, 21 were designated as pilot study participants for training purposes. As these 
participants were not required to  complete assessments at all four time-points (baseline, 3, 6, and 
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12 months), they were removed from all analyses, resulting in a total N of 395. Finally, one 
participant was removed for having insufficient data to be placed in either the anxiety or non-
anxiety group leaving an N of 394 participants included in analyses at baseline. Attrition 
accounted for the loss of another 43 participants over the next year, leaving a final N of 352 
participants included in all analyses. While it is not possible to fully explain why these 43 
participants dropped out of the study, T-tests revealed that at baseline there were no statistically 
significant differences in substance use between the anxiety and non-anxiety groups for any of 
the four substance categories.  
Participants were more likely to be male (81%), Non-Latino (66%), White or Caucasian 
(62%), employed (64%), and single (62%), with an average age of 28 years old. These 
demographic characteristics were similar for the anxiety and non-anxiety groups. For example, 
anxiety group participants were more likely to be male (78%), Non-Latino (64%), White or 
Caucasian (63%), employed (56%), and single (62%), with an average age of 29 years old; and 
non-anxiety group participants were more likely to be male (82%), Non-Latino (67%), White or 
Caucasian (61%), employed (68%), and single (62%), with an average age of 28 years old. See 




Study Sample Demographics 
Tx Group Brief Advice MI MI+Booster 
 Non-Anxiety Anxiety Non-Anxiety Anxiety Non-Anxiety Anxiety 
Age Mean  SD Mean  SD Mean  SD Mean  SD Mean  SD Mean  SD 














Male 69 (77.5) 30 (69.8) 78 (86.7) 36 (78.3) 60 (82.2) 45 (84.9) 
Female 20 (22.5) 13 (30.2) 12 (13.3) 10 (21.7) 13 (17.8) 8 (15.1) 
Ethnicity             
Latino 28 (31.5) 14 (32.6) 31 (34.4) 17 (37) 24 (32.9) 20 (37.7) 
Race             
Asian or Other 23 (25.8) 2 (.05) 2 (.02) 3 (.07) 1 (.01) 2 (.04) 
Black or African 
American 
18 (20.2) 6 (14) 17 (18.9) 6 (13) 10 (13.7) 8 (15.1) 
White or Caucasian 50 (56.2) 28 (65.1) 55 (61.1) 31 (67.4) 49 (67.1) 30 (56.6) 
Employment Status             
Employed 57 (64) 21 (48.8) 63 (70) 23 (50) 50 (68.5) 36 (67.9) 
Unemployed 22 (24) 15 (34.9) 14 (15.6) 16 (34.8) 16 (21.9) 9 (17) 
Not in the work force 10 (11.2) 7 (16.3) 13 (14.4) 7 (15.2) 7 (9.6) 8 (15.1) 
Marital Status             
Single, never married 60 (67.4) 22 (51.2) 52 (57.8) 31 (67.4) 43 (58.9) 36 (67.9) 
Married 8 (9) 2 (4.7) 15 (16.7) 5 (10.9) 7 (9.6) 4 (7.5) 
Separated 5 (5.6) 3 (7) 2 (2.2) 2 (4.3) 3 (4.1) 2 (3.8) 
Divorced 8 (9) 9 (20.9) 12 (13.3) 5 (10.9) 5 (6.8) 6 (11.3) 
Widowed 0 (0) 0 (0) 1 (1.1) 0 (0) 0 (0) 0 (0) 
Living together, but not 
married 
8 (9) 7 (16.3) 8 (8.9) 3 (6.5) 15 (20.5) 5 (9.4) 
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While data about participants’ military service were  not available for this 
dissertation, the project TIP sample is similar to that of the United States armed forces 
(Department of Defense, 2016; Militaryonesource, 2016). For instance, approximately 
80% of this study’s sample is male compared to the military which is comprised of 
approximately 79% males. Furthermore, in regard to race and ethnicity, the sample 
makeup is predominantly White or Caucasian (62%), with an average age of 29 years old 
compared to the military which is also predominantly White or Caucasian (65%), with an 
average age of 28.5 years old. Therefore, this dissertation will serve as a proxy for 
military members and results from analyses are expected to be relatable to both civilian 
and military populations.  
Measures and Study Variables 
SOCIODEMOGRAPHIC FACTORS. The demographic characteristics for this 
dissertation include age, gender, race/ethnicity, employment status, and marital status. 
ANXIETY. Respondents were grouped into either the anxiety (N=142) or non-
anxiety (N=252) groups based on BSI anxiety subscale scores. Previous research has 
identified a t-score of 62 on the Brief Symptom Inventory (BSI)-18 anxiety subscale as a 
cutoff for clinically significant anxiety symptomology. The BSI is used to evaluate 
psychiatric disorders by collecting data directly from patients using either a 53 or 18 item 
test, and can be used to measure patient progress and psychological distress (Derogatis 
and Spencer, 1993). The BSI-18 was used in Project TIP to measure three psychological 
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symptom dimensions (somatization, depression, and anxiety). For the purposes of this 
dissertation, only items pertaining to the anxiety subscale will be used.   
Participants who scored above a 62 on the BSI anxiety subscale were categorized 
as the anxiety group and those who scored a 62 or below were categorized as the non-
anxiety group. However, there may be some room for error among those who score at or 
near the cutoff point. For instance, is someone with a score of 62 significantly less 
anxious than someone with a score of 63? In examining this study’s sample no individual 
cutoff score was near the actual cutoff point with the nearest points more than three 
points away in either direction.  
SUBSTANCE USE. In the TIP study, participants were asked about their use of a 
variety of substances including alcohol, marijuana, and cocaine. For this dissertation, the 
measure of substance use will be based on percent days abstinent (PDA) in the last 90 
days assessed at 3, 6, and 12 months. The number of days a participant endorsed using 
was divided by 90 to calculate PDA. This dissertation will focus on four substance 
categories: any drug, alcohol, marijuana, and cocaine. The category of any drug includes 
all drugs surveyed in this dissertation (including alcohol, marijuana, and cocaine). The 
variable percent days abstinent (PDA) was created using participants’ responses 
regarding each substance endorsed, obtained through TimeLine Follow Back (TLFB) 
procedures (described below).  
The TLFB method is an interview technique used to aid subjects in 
retrospectively measuring specific behaviors, in this case, percent days abstinent from 
substance use. The common procedure for this technique is to provide the subject with a 
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calendar and ask him or her to provide retrospective estimates of their daily substance use 
over a specified period of time up to 12 months. The TLFB can be administered by an 
interviewer or self-administered and takes between 25 to 30 minutes to complete (Sobell 
& Sobell, 1992). A study trained staff member administered the TLFB in Project TIP. 
TRANSTHEORETICAL MODEL (TTM) INSTRUMENTS. The transtheoretical model 
consists of various constructs (i.e., processes of change, self-efficacy, decisional balance, 
Readiness to Change), which were measured in Project TIP with the tools listed below.  
Process of Change Questionnaire (PCQ). An individual’s processes of change 
were originally assessed using the 40-item PCQ (Petrocelli, 2002; Prochaska et al., 1988). 
Project TIP used an adapted 33-item PCQ self-report scale that measured 10 experiential 
and behavioral processes of change on a Likert scale from 1 (never) to 5 (repeatedly). 
Previous studies have established the PCQ’s reliability and validity for various behaviors 
for drug users, including multidrug use (Belding, Iguchi, Lamb, & Lakin, 1995). Using a 
sample of cocaine-dependent patients in an outpatient program, Stotts et al. (2001) 
determined that Cronbach’s alpha was .82 for the experiential subscale was .82 and for 
the behavioral subscale.  
Abstinence Self-Efficacy Scale (ASE). This 31-item, self-report ASE measure, 
which contains four sub-scales (negative affect, social situations, craving and withdrawal, 
and personal problems), assesses an individual’s self-efficacy to abstain from alcohol 
and/or other drug use, based on Bandura's construct of self-efficacy (DiClemente, 
Carbonari, Montgomery, & Hughes, 1994). Participants select a rating on a 5-point Likert 
scale to indicate their confidence to abstain from a substance across different high-risk 
 52 
situations. Additionally, using a parallel set of items on a 5-point Likert scale, 
participants indicate temptation to use in each situation. This measure has been utilized in 
various settings and populations (Kim, Kim, & Gulick, 2009) and has been translated for 
use internationally, including in Ghana (Glozah, Adu, & Komesuor, 2015), Germany 
(Zingg et al., 2009), and Korea (Yang et al., 2017). This scale has been found to be high 
reliability when applied to cocaine, with Cronbach’s alphas for the subscale scores 
ranging from .82 to .88 (Rosenbloom,1991).  
Decisional Balance (DB) Scale. According to (Prochaska and Velicer (1997), DB 
reflects how individuals weigh the pros and cons of changing a behavior. This 
dissertation employs a 12-item measure to capture how participants rate the importance 
of changing a behavior through pros and cons for change. Participants rate how important 
a behavior is to them with scores ranging from 1 to 5 with 1 being the least important. 
Responses include, “not at all” “a little bit” “some” “quite a bit” or “a lot”. The DB 
scale has demonstrated a high level of internal consistency when applied to cocaine with 
a Cronbach’s alpha of .86 for the Pros subscale and .87 for the Cons subscale.  
University of Rhode Island Change Assessment (URICA) Scale. The URICA 
scale is used to measure an individual’s attitude toward readiness to change (DiClemente 
et al, 1991). The measure consists of 32 items designed to represent the four primary 
stages of change (i.e. precontemplation, contemplation, action, and maintenance). Each 
subscale, representing each stage of change, contains eight items (Dozois, Westra, 
Collins, & Garry, 2004). Responses are given on a 5-point Likert scale ranging from 1 
(strong disagreement) to 5 (strong agreement). The subscales can be combined 
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arithmetically to yield a second-order continuous Readiness to Change score that can be 
used to assess readiness to change at entrance to treatment.  This scale has demonstrated 
reliability in multiple samples and among a wide array of studies assessing addiction and 
substance use disorders (Field, Adinoff, Harris, Ball, & Carroll, 2009). DiClemente and 
Hughes (1990) reported that Cronbach’s alpha ranged from .69 to .82, while in another 
study, Project MATCH Cronbach’s alphas ranged from .68 to .85 (Carbonari & 
DiClemente, 2000). In the current study the URICA will be used to create a readiness 
score which is derived by adding the subscale means of contemplation, action, and 
maintenance, and subtracting the subscale mean of precontemplation from that sum. 
PRELIMINARY DATA SCREENING 
Missing Data 
At baseline no missing data were identified. At the 3-month time point, 26 cases were 
missing. The missing data was assumed to be missing completely at random (MCAR), 
based on a missing data analysis, Little’s MCAR test: Chi-Square = .00, p = 1.00. This 
was also the case for the 12-month time point where 43 cases were assumed MCAR 
based on Little’s MCAR test: Chi-Square = .00, p = 1.00. However, at the 6-month time 
point, 27 cases were identified as missing, and these were assumed to be missing at 
random (MAR): Chi-Square = 26.22, p = 0.00. Given that t-tests at baseline revealed no 
significant differences of substance use between these 27 participants and the rest of the 
participants in the study, and as no other time points revealed significant patterns of 
missing data, there is no reason to believe that the data missing at this timepoint are 
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different. Therefore, no imputation will be performed, and listwise deletions will be 
employed for future analysis to eliminate the missing data. All remaining data will be 
used for further analysis based on the Hair et al.’s (2015) recommendations for 
identifying missing data and applying remedies.  
Outliers and Violations of Normality 
Prior to running any analyses, variables were screened for assumptions of normality, 
outliers, and skewness. Histograms were run on all dependent variables as well as the 
only continuous independent variable, age. This revealed the following: The variable age, 
was judged to be positively skewed, but given the small number of participants in the tail 
of the histogram, this was not deemed to be significantly problematic. The variables 
alcohol and cocaine were negatively skewed and both cannabis and any drug were 
bimodal. In each of these cases, transformations were ruled out because they could not 
adequately address both the bimodal distributions and skew of the variables. After 
converting variables to Mahalanobis Distance scores and running a descriptive analysis, 4 
multivariate outliers were identified. When apparent outliers were eliminated, there was 
no substantive difference in results from analyses with and without outliers. As there 
were so few outliers compared to the overall number of participants, 352, and as it is 
impossible to dispute they do not represent some portion of the larger population, the 




To check for potential treatment effects, analyses were run by treatment 
conditions (brief advice, MI, and MI plus a booster) between anxiety and non-anxiety 
groups. Analyses did not reveal a treatment effect at any time for any substance between 
the two groups.  Therefore, analyses were collapsed across treatment conditions to 
include comparisons between anxiety and non-anxiety groups.   
Baseline T-tests for Substance Use Outcomes  
 An independent samples t-test was performed to assess whether average substance 
use (as measured by percent days abstinent) differed between anxiety and non-anxiety 
participants at baseline. Substance use categories included all drugs, alcohol, marijuana 
(cannabis), and cocaine (see Table 5.1). A test of homogeneity revealed a violation 
between the two groups for the dependent variable cocaine. Therefore, the corrected 
analysis results, where equal variances were not assumed, are presented for cocaine with 
a Levene’s F= 28.69, p < .001. There were significant differences between the anxiety 
and non-anxiety groups for three of the four substance use categories: alcohol, t(392)= 
2.430, p= .016; cannabis, t(392)= -2.42, p= .016; cocaine, t(174)= 2.831, p =.005.  Any 
drug was the only category that did not differ significantly, t(392)= -1.19, p= .235. An 
examination of the means between the two groups provides additional insight. In the case 
of alcohol and cocaine, the non-anxiety groups showed more days abstinent (PDA), 




Baseline t-tests comparing anxiety and non-anxiety groups on substance use 









Alcohol Equal variances 
assumed 
2.430 392 .016 .015 .138 




392 .235 -.116 .029 




392 .016 -.165 -.017 
Cocaine Equal variances not 
assumed 
2.831 174 .005 .009 .050 
Note: p  < .05 
Table 5.2 
PDA means by anxiety group for all substances at baseline  
 Group Mean Std. Deviation 
Alcohol Non-Anxiety .75 .29 
Anxiety .67 .31 
Any Drug Non-Anxiety .45 .36 
Anxiety .50 .34 
Cannabis Non-Anxiety .50 .36 
Anxiety .59 .36 
Cocaine Non-Anxiety .98 .05 




Repeated Measures for Substance Use Outcomes  
Substance use outcomes were examined through General Linear Model (GLM) 
repeated measures analyses. For these analyses, four separate repeated measures were 
conducted for each of the four substances, where each substance was examined across the 
four time points. Interactions were investigated using multivariate tests (see Table 5.3). 
Of the four substances, only cocaine had a significant interaction effect, Wilks' λ = .97, p 
= .006. 
Table 5.3 
Interaction between anxiety groups across PDA Substance Use Outcomes over time 
 Wilks' λ  F Sig 
Alcohol .99  1.51 .212 
Any Drug 1.00  .58 .631 
Cannabis 1.00  .25 .859 
Cocaine .97  4.24 .006 
Note: p  < .05 
There were no interaction effects of alcohol across time by anxiety group, any 
drug across time by anxiety group, or cannabis across time by anxiety group (see Figures 
5.1 through 5.3 and Table 5.3). However, there was a significant interaction effect for 
cocaine across time by anxiety group (see Table 5.3 and Figure 5.4). Yet, parameter 
estimates identified that the two groups only differed at baseline for cocaine. In 
comparison, those with anxiety reported fewer days abstinent on average than those 
without anxiety (see Tables 5.4 through 5.7). 
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Figure 5.1. PDA for alcohol between anxiety and non-anxiety groups over time. p = * < 
.05, ** < .01, *** < .001 
 
Table 5.4 
Comparison of Anxiety versus Non-anxiety groups on PDA for alcohol: baseline, 3-, 6-, 
and 12-months 
Alcohol b (SE) t p Lower CI Upper CI 
Baseline .08 (.03) 2.42 .016 .02 .14 
3 Months .06 (.03) 2.05 .041 .00 .11 
6 Months .08 (.03) 2.54 .012 .02 .14 
12 Months .04 (.03) 1.47 .143 -.01 .10 














Figure 5.2. PDA for any drug between anxiety and non-anxiety groups over time. p = * < 
.05, ** < .01, *** < .001 
 
Table 5.5 
Comparison of Anxiety versus Non-anxiety groups on PDA for any drug: baseline, 3-, 6-, 
and 12-months 
Any Drug b (SE) t p Lower CI Upper CI 
Baseline -.04 (.04) -1.06 .289 -.12 .04 
3 Months -.06 (.04) -1.53 .127 -.14 .02 
6 Months -.02 (.04) -.56 .577 -.11 .06 
12 Months -.05 (.04) -1.35 .18 -.13 .03 















Figure 5.3. PDA for cannabis between anxiety and non-anxiety groups over time. p = * < 
.05, ** < .01, *** < .001 
 
Table 5.6 
Comparison of Anxiety versus Non-anxiety groups on PDA for cannabis: baseline, 3-, 6-, 
and 12-months 
Cannabis b (SE) t p Lower CI Upper CI 
Baseline -.10 (.04) -2.46 .014 -.18 -.02 
3 Months -.10 (.04) -2.55 .01 -.17 -.02 
6 Months -.07 (.04) -1.67 .096 -.15 .01 
12 Months -.08 (.04) -2.12 .035 -.16 -.01 














Figure 5.4. PDA for cocaine between anxiety and non-anxiety groups over time. p = * < 
.05, ** < .01, *** < .001 
Table 5.7 
Comparison of Anxiety versus Non-anxiety groups on PDA for cocaine: baseline, 3-, 6-, 
and 12-months 
Cocaine b (SE) t p Lower CI Upper CI 
Baseline .03 (.01) 3.11 .002 .01 .05 
3 Months -.00 (.01) -39 .698 -.01 .01 
6 Months .00 (.01) .27 .792 -.02 .02 
12 Months .01 (.01) 1.30 .19 -.00 .02 
Note: p  < .05 
The main effects for anxiety and non-anxiety groups across the four substances 
show that the two groups differed on alcohol and cannabis use but not on any drug or 
cocaine (see Table 5.8). A comparison of means across time showed that the anxiety 
group reported significantly fewer  PDA for alcohol (see Figure 5.1), and greater PDA 













Main Effect for Percent Days Abstinent by Substance 




Alcohol 1.34 (1) 6.16 .014 
Any Drug .65 (1) 1.80 .18 
Cannabis 2.44 (1) 6.92 .009 
Cocaine .03 (1) 2.27 .132 
Note: p  < .05 
Multivariate analyses revealed a time effect for each of the four substances 
analyzed (see Table 5.9). In each case, the greatest improvement in PDA for both anxiety 
and non-anxiety participants occurred at 3 months. At six months, these improvements 
seemed to diminish. Finally, at 12 months, both anxiety and non-anxiety groups seemed 
to rebound with improvement in PDA for all substance use outcomes from baseline to 12 
months. In summary, although there were between subject effects for the anxiety and 
non-anxiety groups and a time effect for PDA, there were no significant differences in 
change over time by the anxiety or non-anxiety groups. 
Table 5.9 
Time Effects for Percent Days Abstinent by Substance  
 Wilks' λ F Sig 
Alcohol .78 32.67 (3, 346) .000 
Any Drug .70 48.65 (3, 346) .000 
Cannabis .76 36.68 (3, 346) .000 
Cocaine .91 11.83 (3, 346) .000 
Note: p  < .05  
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Profile Analyses 
Profile Analysis is a special application of multivariate analysis of variance 
(MANOVA) for repeated measures that can be used when several dependent variables 
(e.g. subscales of the TTM measures) are measured at one time. This analysis provides 
various tests of interest, but the only test of interest for this study is the test of 
parallelism, which is equivalent to the interaction effect in a standard MANOVA and 
assesses the patterns of the mean values of the dependent variables. Rejection of the null 
hypothesis of parallelism would suggest a parallelism effect, indicating differences in the 
overall shape of the profiles (Tabachnick & Fidell, 2012). Profile analyses, comparing the 
anxiety group to the non-anxiety group were used to examine the process of change using 
TTM constructs as dependent variables (i.e. decisional balance, self-efficacy, and 
processes of change, and readiness) at four time points (baseline, 3-, 6-, and 12- months) 
for both cannabis and cocaine. Because project TIP did not collect TTM construct data 
for alcohol or any drug use, they could not be included in these analyses.  
CANNABIS 
Cannabis TTM constructs were compared at all four time points (i.e. URICA 
precontemplation, contemplation, action, maintenance; Decisional Balance, pros and 
cons for change; confidence; temptation; and Processes of Change, experiential and 
behavioral). The first three time points there were significant parallelism effects between 




TTM Constructs Multivariate Tests for parallelism for Cannabis 
 Wilks' λ F Sig 
Baseline .88 4.68 (9, 300) .000 
3 months .91 2.56 (9, 241) .008 
6 months .91 2.56 (9, 246) .008 
12 months .96 1.35 (9, 283) .212 
Note: p  < .05 
Table 5.11 shows that at baseline, all constructs differed significantly between the 
two groups, with the exception of the precontemplation construct, (p=.162). Of those that 
were significantly different, the anxiety group reported greater engagement in 
contemplation (p < .001), action (p < .001), and maintenance (p < .001) than the non-
anxiety group. The anxiety group also reported more pros (p = .008) and cons for change 
(p < .001), greater temptation (p < .001), and greater use of the experiential (p < .001), 
and behavioral processes of change (p < .001).  Figure 5.5 presents a comparison of 











Baseline TTM Construct Parameter Estimates of Between Subjects Effects for Cannabis 
Baseline b (SE) t p  Lower CI Upper CI 
Pre-contemplation 1.66 (1.18) 1.40 .162  -.67 3.98 
Contemplation -6.78 (1.133) -5.98 .000  -9.01 -4.55 
Action -5.15 (1.52) -4.47 .000  -7.41 -2.88 
Maintenance -6.08 (1.128) -5.39 .000  -8.29 -3.86 
DB Pro for change -3.09 (1.16) -2.67 .008  -5.38 -.81 
DB Con for change -4.59 (1.19) -3.87 .000  -6.92 -2.26 
Confidence 3.20 (1.17) 2.73 .007  .90 5.50 
Temptation -4.32 (1.17) -3.68 .000  -6.63 -2.01 
Experiential  -4.59 (1.16) -3.95 .000  -6.87 -2.30 
Behavioral -4.35 (1.15) -3.78 .000  -6.61 -2.08 




Figure 5.5. Baseline mean differences in TTM constructs between anxiety and non-
anxiety groups for cannabis. P=Pre-contemplation, C=contemplation, A=Action, 
M=Maintenance, Pro=DB Pro for Change, Con=DB Con for Change, Conf=Confidence, 
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Table 5.12 and Figure 5.6 show that the only change from baseline to the 3-month 
time point, was in the confidence construct, which became non-significant (p=.182). The 
anxiety group continued to engage more in contemplation (p < .001), action (p < .001), 
and maintenance (p < .001), than the non-anxiety group and reported more pros (p = 
.013) and cons for change (p = .017), greater temptation (p = .030), as well as greater use 
of the experiential (p < .001), and behavioral processes of change (p < .001). 
Table 5.12 
3 Month TTM Construct Parameter Estimates of Between Subjects Effects for Cannabis 
3 Months b (SE) t p Lower CI  Upper CI 
Pre-contemplation .67 (1.34) .50 .616 -1.96  3.30 
Contemplation -6.12 (1.26) -4.85 .000 -8.62  -3.64 
Action -5.10 (1.27) -4.01 .000 -7.61  -2.60 
Maintenance -5.95 (1.27) -4.69 .000 -8.45  -3.45 
DB Pro for change -3.31 (1.32) -2.51 .013 -5.90  -.71 
DB Con for change -3.12 (1.30) -2.40 .017 -5.69  -.55 
Confidence 1.74 (1.30) 1.34 .182 -.82  4.31 
Temptation -2.86 (1.31) -2.19 .030 -5.43  -.29 
Experiential  -4.70 (1.31) -3.59 .000 -7.27  -2.11 
Behavioral -4.71 (1.30) -3.63 .000 -7.27  -2.15 





Figure 5.6. 3-month mean differences in TTM constructs between anxiety and non-
anxiety groups for cannabis. P=Pre-contemplation, C=contemplation, A=Action, 
M=Maintenance, Pro=DB Pro for Change, Con=DB Con for Change, Conf=Confidence, 
Temp=Temptation, Exp=Experiential, Beh=Behavioral. p = * < .05, ** < .01, *** < .001 
 
Table 5.13 and Figure 5.7 show that no further significant changes in use of 
constructs at the 6-month assessment between the two groups. Again, the anxiety group 
engaged more in contemplation (p < .001), action (p = .001), and maintenance (p < .001) 
than the non-anxiety group. The anxiety group also reported more pros (p = .002) and 
cons for change (p = .007), greater temptation (p = .019), and greater use of the 
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6 Month TTM Construct Parameter Estimates of Between Subjects Effects for Cannabis 
6 Months b (SE) t p Lower CI Upper CI 
Pre-contemplation .115 (1.35) .09 .932 -2.55 2.78 
Contemplation -4.92 (1.12) -3.73 .000 -7.51 -2.32 
Action -4.33 (1.33) -3.26 .001 -6.94 -1.72 
Maintenance -5.86 (1.30) -4.52 .000 -8.42 -3.31 
DB Pro for change -4.67 (1.31) -3.19 .002 -6.74 -1.60 
DB Con for change -3.62 (1.34) -2.71 .007 -6.25 -.99 
Confidence 1.87 (1.32) 1.42 .16 -.72 4.47 
Temptation -3.16 (1.34) -2.36 .019 -5.80 -.52 
Experiential  -4.99 (1.33) -3.75 .000 -7.60 -2.37 
Behavioral 5.21 (1.31) -3.98 .000 -7.79 -2.63 
Note: p  < .05 
 
 
Figure 5.7. 6-month mean differences in TTM constructs between anxiety and non-
anxiety groups for cannabis. P=Pre-contemplation, C=contemplation, A=Action, 
M=Maintenance, Pro=DB Pro for Change, Con=DB Con for Change, Conf=Confidence, 
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Table 5.14 and figure 5.8 show that at 12-months there was no longer an overall 
parallelism effect between the anxiety non-anxiety groups. However, an examination of 
the constructs individually revealed that four of the ten constructs remained significant 
(see Table 5.14 and Figure 5.8). Of these, the anxiety group reported greater engagement 
in the contemplation construct (p=.045), greater temptation (p=.05), and greater use of 
the experiential (p = .01), and behavioral processes of change (p=.008). 
Table 5.14 
12 Month TTM Construct Parameter Estimates of Between Subjects Effects for Cannabis 
12 Months b (SE) t p Lower CI Upper CI 
Pre-contemplation .82 (1.23) .67 .506 -1.60 3.23 
Contemplation -2.46 (1.22) -2.02 .045 -4.87 -.061 
Action -1.83 (1.23) -1.48 .14 -4.25 .60 
Maintenance -2.28 (1.23) -1.86 .064 -4.70 .137 
DB Pro for change -1.66 (1.23) -1.36 .18 -4.08 .75 
DB Con for change -1.36 (1.23) -1.11 .27 -3.78 1.06 
Confidence 1.06 (1.23 .86 .39 -1.37 3.48 
Temptation -2.39 (1.23) -1.94 .05 -4.82 .04 
Experiential  -3.14 (1.25) -2.52 .01 -5.59 -.69 
Behavioral -3.29 (1.24) -2.66 .008 -5.73 -.86 





Figure 5.8. 12-month mean differences in TTM constructs between anxiety and non-
anxiety groups for cannabis. P=Pre-contemplation, C=contemplation, A=Action, 
M=Maintenance, Pro=DB Pro for Change, Con=DB Con for Change, Conf=Confidence, 
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TTM constructs (i.e. Readiness precontemplation, contemplation, action, 
maintenance; Decisional Balance pros and cons of change; Self-Efficacy confidence and 
temptation; and Processes of Change experiential and behavioral). were also compared 
for cocaine at all four time points, but only baseline showed parallelism effect between 
the anxiety and non-anxiety groups (see Table 5.15). Parameter estimates for all time 
points are listed in Tables 5.15 through 5.18 and Figures 5.9 through 5.12 for review. 
Table 5.15 
TTM Constructs Multivariate Tests of Parallelism for Cocaine 
 Wilks' λ F Sig 
Baseline .72 3.32 (9, 76) .002 
3 months .81 1.32 (9, 52) .251 
6 months .81 1.61 (9, 61) .132 
12 months .85 1.33 (9, 69) .240 
Note: p  < .05 
BASELINE . Table 5.16 and Figure 5.9 show that nearly all of the constructs for 
cocaine were statistically significant between the two groups at baseline, except for 
precontemplation, (p=.062), and the pros for change (p=.342). Of those that were 
significantly different, the anxiety group reported greater engagement in contemplation (p 
= .006), action (p = .006), and maintenance (p = .016). The anxiety group also reported 
more cons for change (p = .001), greater temptation (p = .014), and greater use of the 





Baseline TTM Construct Parameter Estimates of Between Subjects Effects for Cocaine 
Baseline b (SE) t p Lower CI Upper CI 
Pre-contemplation 4.11 (2.18) 1.89 .062 -.22 8.44 
Contemplation -5.83 (2.08) -2.81 .006 -9.96 -1.70 
Action -6.34 (2.08) -3.05 .003 -10.46 -2.21 
Maintenance -5.207 (2.12) -2.46 .016 -9.41 -1.00 
DB Pro for change -2.10 (2.20) -.96 .342 -6.47 2.27 
DB Con for change -7.32 (2.06) -3.56 .001 -11.41 -3.22 
Confidence 4.56 (2.160) 2.11 .038 .27 8.86 
Temptation -5.40 (2.14) -2.52 .014 -9.66 -1.15 
Experiential  -9.43 (1.95) -4.83 .000 -13.31 -5.56 
Behavioral -5.80 (2.13) -2.73 .008 -10.03 -1.57 
Note: p  < .05 
 
 
Figure 5.9. Mean differences in TTM constructs between anxiety and non-anxiety groups 
at baseline for cocaine. P=Pre-contemplation, C=contemplation, A=Action, 
M=Maintenance, Pro=DB Pro for Change, Con=DB Con for Change, Conf=Confidence, 
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3-MONTHS. At the 3- month time point, only two constructs remained significant 
(see Table 5.17 and Figure 5.10). The anxiety group reported greater engagement 
contemplation (p = .014), and greater use of the experiential processes of change (p = 
.046). 
Table 5.17 
3 Month TTM Construct Parameter Estimates of Between Subjects Effects for Cocaine 
3 Months b (SE) t p Lower CI Upper CI 
Pre-contemplation -.54 (2.56) -.21 .835 -5.66 4.59 
Contemplation -2.53 (2.48) -2.53 .014 -11.25 -1.31 
Action -1.41 (2.53) -1.41 .165 -8.63 1.51 
Maintenance -3.54 (2.60) -1.36 .178 -8.72 1.65 
DB Pro for change -2.93 (2.59) -1.13 .261 -8.11 2.24 
DB Con for change -3.43 (2.52) -1.36 .179 -8.47 1.61 
Confidence 2.66 (2.59) 1.03 .308 -2.52 7.85 
Temptation -2.57 (2.63) -0.98 .331 -7.832 2.68 
Experiential  -5.02 (2.47) -2.04 .046 -9.95 -0.09 
Behavioral -3.52 (2.57) -1.37 .176 -8.67 1.62 





Figure 5.10. Mean differences in TTM constructs between anxiety and non-anxiety 
groups at 3 months for cocaine. P=Pre-contemplation, C=contemplation, A=Action, 
M=Maintenance, Pro=DB Pro for Change, Con=DB Con for Change, Conf=Confidence, 
Temp=Temptation, Exp=Experiential, Beh=Behavioral. p = * < .05, ** < .01, *** < .001 
6-MONTHS. In 6-month time point, the contemplation construct was no longer 
significant between anxiety and non-anxiety groups (see Table 5.18 and Figure 5.11). 
However, two other constructs were significant. The anxiety group reported greater use 
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6 Month TTM Construct Parameter Estimates of Between Subjects Effects for Cocaine 





-.90 .929 -5.09 4.65 
Contemplation -3.37 (2.43) -1.40 .167 -8.23 1.45 
Action -1.22 (2.48) -0.49 .623 -6.16 3.72 
Maintenance -1.85 (2.45) -0.75 .454 -6.74 3.05 
DB Pro for 
change 
-.58 (2.46) -0.24 .815 -5.48 4.32 
DB Con for 
change 
-4.42 (2.36) -1.87 .066 -9.14 0.29 
Confidence .24 (2.38) .10 .921 -4.51 4.99 
Temptation -4.03 (2.40) -1.68 .097 -8.81 0.75 
Experiential  -7.58 (2.26) -3.36 .001 -12.08 -3.08 
Behavioral -5.61 (2.32) -2.41 .018 -10.24 -0.97 
Note: p  < .05 
 
Figure 5.11. Mean differences in TTM constructs between anxiety and non-anxiety 
groups at 6 months for cocaine. P=Pre-contemplation, C=contemplation, A=Action, 
M=Maintenance, Pro=DB Pro for Change, Con=DB Con for Change, Conf=Confidence, 
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12-MONTHS. The final time point revealed three significantly different constructs 
between the anxiety and non-anxiety groups (see Table 5.19 and Figure 5.12) with the 
anxiety group reported greater engagement in maintenance (p = .024), less cons for 
change (p = .047), and greater use of the experiential (p = .011), and behavioral 
processes of change (p = .048).   
Table 5.19 
12 Month TTM Construct Parameter Estimates of Between Subjects Effects for Cocaine 
12 Months b (SE) t p Lower CI Upper CI 
Pre-
contemplation 
1.51 (2.28) .66 .511 -3.03 6.05 
Contemplation -3.60 (2.25) -1.60 .114 -8.08 .88 
Action -3.87 (2.24) -1.72 .089 -8.34 .60 
Maintenance -5.10 (2.21) -2.31 .024 -9.51 -.70 
DB Pro for 
change 
.50 (2.29) .22 .826 -4.05 5.06 
DB Con for 
change 
-4.51 (2.23) -2.02 .047 -8.94 -.07 
Confidence 2.40 (2.27) 1.06 .293 -2.12 6.93 
Temptation -3.26 (2.26) -1.44 .153 -7.75 1.24 
Experiential  -5.71 (2.19) -2.60 .011 -10.07 -1.34 
Behavioral -4.48 (2.23) -2.01 .048 -8.92 -.04 








Figure 5.12. Mean differences in TTM constructs between anxiety and non-anxiety 
groups at 12 months for cocaine. P=Pre-contemplation, C=contemplation, A=Action, 
M=Maintenance, Pro=DB Pro for Change, Con=DB Con for Change, Conf=Confidence, 
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Latent Growth Curve (LGC) Analyses 
Baseline models for all TTM constructs were examined using listwise deletion 
methods, ensuring no missing data were  included in analyses. TTM constructs were 
matched in pairs according to their theoretical contributions to each other: decisional 
balance pros and cons for change; confidence and temptation; and experiential and 
behavioral processes of change. The URICA construct for readiness ([Contemplation + 
Action + Maintenance] – Precontemplation) was isolated as the sole construct in its 
model. Initially each pair of TTM constructs were diagramed. This model represents the 
conceptual model. Modifications were made to the conceptual model and are presented as 
the Level 1 model. Finally, the category of anxiety was added to the model and is 
presented as the Level 2 model.  
Re-specifications from the conceptual model were made based on AMOS output of 
model fit using Comparative Fit Index (CFI), Root Mean Square of Approximation 
(RMSEA), chi square and adjusted chi square values. When model fit was not achieved, 
modification indices were examined, and models were altered based on the most 
influential change suggestions through the SEM output. Error terms (labeled ED1 
through ED 4 and ER1 through ER4) were covaried only on similar time points. For 
example, for confidence and temptation, modification indices suggested covarying the 
error terms of ED3 and ER3. These each represent error terms for time point three (6 
months) for their respective construct (i.e., ED3 = 6 months for the confidence construct). 
When modification indices suggested covarying non-similar time points (e.g., ED1 and 
ED3), the model was not altered. The labels of ER and ED have no real meaning other 
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than to signify error terms for each construct (e.g., ED for confidence and ER for 
temptation).  
Following completions of model modifications from the conceptual model (see Tables 
5.20 through 5.27 for model modification details for both cannabis and cocaine), the new 
(re-specified) model represents the Level 1 model and was tested using the full data set 
with Maximum Likelihood estimation of missing values (see Figures 5.13 through 5.34). 
The final model was then run with the anxiety variable comparing the two groups and 
represents the Level 2 model. As noted, this analysis requires the use of modifications 
indices to identify suggested model alterations. However, the software requires that there 
be no missing data in order to provide modification indices. Therefore, initial models 
used only partial data (no missing data) in order to obtain modification indices and make 
model alterations. Once the conceptual model modifications were complete, the Level 1 
and Level 2 models were run with the complete data set. Results of these analyses are 
first described for cannabis (see Table 5.24 for a summary of cannabis findings) followed 
by the results for cocaine (see Table 5.29 for a summary of cocaine findings).  
Cannabis Confidence and Temptation  
CONCEPTUAL MODEL 
 
The conceptual model of confidence and temptation for cannabis (see Figure 
5.13) was first run with the complete data set and did not achieve sufficient model fit (see 
Table 5.20). Modification indices suggested covarying the confidence intercept 
(Conf_ICEPT) to the temptation intercept (Temp_ICEPT) as well as the confidence slope 
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(Conf_SLOPE) to the temptation slope (Temp_SLOPE). However, model fit was still not 
achieved, and modification indices further suggested covarying time points 1 (ED1 to 
ER1), 2 (ED2 to ER2), and 3 (ED3 to ER3), between the constructs. Covariances were 
then examined, showing that the paths form confidence intercept (Conf_ICEPT) to 
confidence slope (Conf_SLOPE) as well as temptation intercept (Temp_ICEPT) to 
temptation slope (Temp_SLOPE) were not significant. The non-significance of these 
paths indicates that participants’ rate of change over time in confidence or temptation was 
not significantly affected by where they started on either construct. Therefore, these paths 
were removed for the Level 1 model (see Figure 5.14).  
Table 5.20 
LGC Cannabis Self-Efficacy TTM Variable Modification Table 
Model 
Level 
Model Description Model X2 Df CFI RMSEA 
1 Conf & Temp      
1 Base Model (Run with no missing data) 1 382.4 26 .688 .242 
 Covaried: 
Conf ICEPT and Temp ICEPT; Conf SLOPE and 
Temp Slope; ED3 and ER3; ED2 and ER2; ED1 
& ER1 
Eliminated:  
Conf ICEPT and Conf SLOPE; Temp ICEPT and 
Temp SLOPE 
2 69.0 23 .960 .092 
 Complete Data Model (Run with missing data) 3 67.2 23 .965 .070 




Figure 5.13. Conceptual model of confidence and temptation for cannabis 
LEVEL 1.  
Means were examined in the Level 1 model and were significant for both 
confidence and temptations intercepts and slopes. Specifically, participants initially 
reported higher levels of confidence (Estimate: 3.06, p < .001) than temptation (Estimate: 
2.59, p < .001) and over time, participants reported significant increases in confidence 
(Estimate: .05, p = .006) and significant decreases in temptation (Estimate: -.06, p < 
.001).  
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When covariances were re-examined in the Level 1 model, the intercept for 
confidence was negatively related to the intercept for temptation (Estimate: -.496, p < 
.001). This indicates that at baseline participants with higher levels of confidencealso had 
lower levels of temptation. Additionally, the slope for confidence was negatively related 
to the slope for temptation (Estimate: -.03, p < .001), indicating that as participants’ 
confidence increased, their temptation levels decreased.  
An examination of variances showed significant intercepts for both confidence 
(Estimate: .59, p < .001) and temptation (Estimate: .66, p < .001) as well as the slopes for 
both confidence (Estimate: .05, p < .001) and temptation (Estimate: .03, p < .001). This 
indicates that there was significant variation between participants at the starting points for 
both confidence and temptations; and that participants differed significantly in their rate 
of change for both confidence and temptation over time. This variation is further explored 
using a predictor variable by dividing participants into anxiety and non-anxiety groups in 
the level 2 model below.   
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Figure 5.14. Level 1 model of confidence and temptation for cannabis 
LEVEL 2. 
 
The level 2 model (see Figure 515) incorporates the predictor variable of anxiety and 
regression weights were examined. In this model, both the paths from the anxiety 
variable to the intercepts for confidence (Estimate: -.31 p = .006) and temptation 
(Estimate: .41 p < .001) were significant, meaning the anxiety group initially reported 
lower levels of confidence, and higher levels of temptation than the non-anxiety group. 
However, neither of the paths from the anxiety variable to the slopes for confidence nor 
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temptation were significant, indicating that the anxiety groups did not differ significantly 
in rate of change for either construct over time.  
 
Figure 5.15. Level 2 model of confidence and temptation for cannabis 
Cannabis Decisional Balance 
CONCEPTUAL MODEL.  
 
The DB conceptual model for cannabis (see Figure 5.16) was first run with the 
complete data set and did not achieve sufficient model fit (see Table 5.21). Modification 
indices suggested covarying the pros for change intercept (DBPro_ICEPT) to the cons for 
change intercept (DBCons_ICEPT) as well as the pros for change slope 
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(DBPro_SLOPE) to the cons for change slope (DBCons_SLOPE). However, model fit 
was still not achieved, and modification indices further suggested covarying time points 1 
(ED1 to ER1), 2 (ED2 to ER2), and 3 (ED3 to ER3), between the constructs.  
Covariances were then examined, showing that the paths from the pros for change 
intercept (DBPros_ICEPT) to pros for change slope (DBPros_SLOPE), as well as cons 
for change intercept (DBCons_ICEPT) to cons for change slope (DBCons_SLOPE) were 
not significant. The non-significance of these paths indicates that participants’ rate of 
change over time in their perceived importance of pros or cons for change was not 
significantly affected by where they started on either construct. Therefore, these paths 
were removed.  
Table 5.21 
LGC Cannabis DB TTM Variable Modification Table 
Model 
Level 
Model Description Model X2 Df CFI RMSEA 
1 DB      
1 Base Model (Run with no missing data) 1 183.4 26 .737 .166 
 Covaried: 
Conf ICEPT and Temp ICEPT; Conf SLOPE and 
Temp Slope; ED3 and ER3; ED2 and ER2; ED1 
& ER1 
Eliminated:  
Conf ICEPT and Conf SLOPE; Temp ICEPT and 
Temp SLOPE 
2 35.1 23 .981 .049 
 Complete Data Model (Run with missing data) 3 43.9 23 .972 .048 




Figure 5.16. Conceptual model of Decisional Balance for cannabis 
LEVEL 1.  
 
Means from the Level 1 model for pros and cons for change for cannabis (see 
Figure 5.17) were examined and showed that both the intercepts for pros and cons for 
change were significant and that participants initially reported greater pros for change 
(Estimate: 2.11, p < .001), than cons for change (Estimate: 1.65, p < .001).  Additionally, 
the slope for pros for change was significant (Estimate: -.08, p < .001), meaning 
participants reported significant decreases in pros for change over time. Covariances 
from this model showed that the intercept for pros for change was positively related to 
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the intercept for cons for change (Estimate: .16, p < .001). This indicates that participants 
who rated higher perceived importance in pros for change also rated higher perceived 
importance in cons for change. Additionally, the slope for pros for change was positively 
related to the slope for cons for change (Estimate: .01, p < .001). An examination of 
mean scores over time indicated that participants reported a decrease in perceived 
importance of pros and cons for change over time, meaning that as participants perceived 
importance of pros for change decreased, there was a similar rate of decrease in their 
perceived importance of cons for change.   
Variances in the intercepts for both pros for change (Estimate: .44, p < .001) and 
cons for change (Estimate: .27, p < .001) were significant. This indicates that there was 
significant variation between participants at the starting points for both pros and cons for 
change. Additionally, the slope for cons for change (Estimate: .03, p < .001) was 
significant, meaning that participants rate of change for perceived importance of cons for 
change over time differed significantly. This variation was further explored using a 
predictor variable by dividing participants into anxiety and non-anxiety groups in the 
level 2 model below. 
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Figure 5.17. Level 1 model of Decisional Balance for cannabis 
LEVEL 2.  
 
The level 2 model of DB for cannabis (see Figure 5.18) incorporates the predictor 
variable of anxiety and regression weights were examined. In this model, the path from 
the anxiety variable to the intercepts for both pros (intercept = .34, p < .001) and cons 
(intercept = .35, p < .001) for change showed significant group differences at baseline. 
This indicates that the anxiety group initially reported higher perceived importance of 
both pros and cons for change than the non-anxiety group. When the paths from the 
anxiety variable to slopes for these constructs were reviewed there was not a significant 
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group difference in the rate of change for pros for change over time. However, the slope 
for cons for change (Estimate: -.06, p < .001) was significant, indicating that the anxiety 
group’s decrease in perceived importance of cons for change occurred at a lower rate 
than the non-anxiety group.  
 
Figure 5.18. Level 2 model of Decisional Balance for cannabis 
 
Cannabis Processes of Change 
CONCEPTUAL MODEL.  
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The conceptual model of POC for cannabis (see Figure 5.19) was first run with 
the complete data set and did not achieve sufficient model fit (see Table5.22). 
Modification indices suggested covarying the experiential processes of change intercept 
(EXP_ICEPT) to the behavioral processes of change intercept (BEH_ICEPT) as well as 
the experiential slope (EXP_SLOPE) to the behavioral slope (BEH_SLOPE). However, 
model fit was still not achieved, and modification indices further suggested covarying 
time points 1 (ED1 to ER1), 2 (ED2 to ER2), and 3 (ED3 to ER3) between the constructs. 
Covariances were then examined, showing that the paths from the experiential intercept 
(EXP_ICEPT) to experiential slope (EXP_SLOPE), as well as behavioral intercept 
(BEH_ICEPT) to behavioral slope (BEH_SLOPE) were not significant. These non-
significant paths indicate that participants’ rate of change over time in how they engaged 
in experiential and behavioral processes of change was not significantly affected by 
where they started on either construct. Therefore, these paths were removed.  
Table 5.22 
LGC Cannabis POC TTM Variable Modification Table 
Model 
Level 
Model Description Model X2 Df CFI RMSEA 
1 POC      
1 Base Model (Run with no missing data) 1 876.5 26 .491 .377 
 Covaried: 
Conf ICEPT and Temp ICEPT; Conf SLOPE and 
Temp Slope; ED3 and ER3; ED2 and ER2; ED1 
& ER1 
Eliminated:  
Conf ICEPT and Conf SLOPE; Temp ICEPT and 
Temp SLOPE 
2 62.1 23 .977 .086 
 Complete Data Model (Run with missing data) 3 72.7 23 .975 .074 




Figure 5.19. Conceptual model of Processes of Change for cannabis 
LEVEL 1.  
 
In the Level 1 POC model for cannabis (see Figure 5.20), means for both 
experiential and behavioral intercepts were significant, as well as the experiential slope, 
indicating that participants initially reported greater use of behavioral processes 
(Estimate: 1.93, p < .001) than the experiential processes (Estimate: 1.76, p < .001) and 
that over time, participants reported a significant decrease in their use of experiential 
processes (Estimate: -.04, p < .001). Covariances for this model showed the intercept for 
experiential processes of change was positively related to the intercept for behavioral 
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processes of change (Estimate: .29, p < .001). This indicates that participants who 
reported more engagement in experiential processes also reported more engagement in 
behavioral processes. Additionally, experiential the slope for experiential processes was 
positively related to the behavioral slope (Estimate: .02, p < .001). An examination of 
mean scores over time indicated that participants reported decreased engagement in 
experiential and behavioral processes over time, meaning that as participants reported a 
decrease in their use of experiential processes, they also reported a decrease in their use 
of behavioral processes.   
An examination of variances showed that intercepts for both experiential 
(Estimate: .27, p < .001) and behavioral (Estimate: .41, p < .001) processes of change 
significant, as were the slopes for both experiential (Estimate: .02, p < .001) and 
behavioral (Estimate: .03, p < .001) processes. This indicates that there was significant 
variation between participants at the starting points for both experiential and behavioral 
processes; and that participants significantly differed in their rate of change for both 
processes of change over time. This variation was further explored using a predictor 
variable, i.e., dividing participants into anxiety and non-anxiety groups, as shown a Level 
2 model (See Figure5.21).  
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Figure 5.20. Level 1 model of Processes of Change for cannabis 
LEVEL 2.  
 
Results from the level 2 model of POC for cannabis (see Figure 5.21) show that the 
paths from the anxiety variable to the intercepts for both the experiential (intercept = .31, 
p < .001) and behavioral (intercept = .37, p < .001) processes were significant. This 
indicates that the anxiety group reported higher use of both processes at baseline. 
However, the paths from the anxiety construct to the slopes for the experiential and 
behavioral processes were not significant, meaning the groups’ rates of change did not 
differ significantly from each other in their use of experiential or behavioral processes. 
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Figure 5.21. Level 2 model of Processes of Change for cannabis 
 
Cannabis Readiness 
CONCEPTUAL/LEVEL 1 MODEL. 
 
The conceptual model of readiness for cannabis (see Figure 5.22) was first run 
with the complete data set and did not achieve sufficient model fit. Modification indices 
did not suggest any changes to this model. Because no alterations were made to the 
conceptual model, it also represents the level 1 model. Although, model fit was not 
initially achieved in the conceptual/level 1 model using the partial data set (no missing 
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data), it was later achieved using the complete data set. Model fit further improved with 
the addition of the predictor variable in the level 2 model.  Means were examined and 
showed the readiness intercept was significant (Estimate: 5.02, p < .001), while the 
readiness slope was not, indicating participants’ readiness to change over time did not 
differ. Covariances from this model showed that the readiness intercept was negatively 
related to the readiness slope (Estimate: -.28, p = .008), indicating that the higher 
participants rated their initial readiness to change, the more it decreased over time.  
An examination of variances showed both the readiness intercept (Estimate: 1.68, 
p < .001) and slope (Estimate: .13, p < .001) were significant. This indicates that there 
was significant variation between participants at the starting points for readiness; and that 
participants’ readiness significantly differed in rate of change over time. This variation is 
further explored using a predictor variable that divided participants into anxiety and non-
anxiety groups, as shown in the level 2 model (see Figure 5.23).  
Table 5.23 
LGC Cannabis Readiness TTM Variable Modification Table 
Model 
Level 
Model Description Model X2 Df CFI RMSEA 
1 Readiness      





2 37.3 8 .931 .131 
 Complete Data Model (Run with missing data) 3 35.4 8 .942 .093 




Figure 5.22. Conceptual and Level 1 model of Readiness for cannabis  
LEVEL 2.  
 
In the level 2 model of readiness for cannabis (see Figure 5.23) the significance of the 
path from the anxiety variable to the readiness intercept indicates that at baseline the 
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anxiety group reported higher readiness to change than the non-anxiety group (Estimate: 
1.68, p < .001). The path from the anxiety variable to the readiness slope was also 
significant (Estimate: -.25, p < .001), indicating that participants with anxiety reported a 
lower rate of change in their readiness to change than those without anxiety. Mean scores 
over time were examined and showed that participants tended to report a decrease in 
readiness to change over time. In other words, while participants overall showed a 
decrease in readiness to change over time, the anxiety group’s readiness to changed 
decreased at a slower rate.  
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Figure 5.23. Level 2 model of Readiness for cannabis  
To aid in interpretation of the LGC results from the TTM constructs listed above (i.e., 
confidence and temptation, pros and cons of change, experiential and behavioral 
processes of change, and readiness to change) Table 5.24 presents a summary of LGC 
findings for cannabis.  
 99 
Table 5.24 
LGC Summary Table of TTM constructs for cannabis 




Experiential Behavioral Readiness 
Means         
Intercept 3.06*** 2.59*** 2.11*** 1.65*** 1.76*** 1.93*** 5.02*** 
Slope .05** -.06*** -.08*** -.03 -.04*** .01 -.01 
Covariance        




Estimate -.50*** .16*** .29*** 
Slope Conf <-->Temp Pros <-->Cons Exp <-->Beh 
Estimates -.03*** .01*** .02*** 
Variance        
Intercept .59*** .66*** .44*** .27*** .27*** .41*** 4.47*** 
Slope  .05*** .03*** <.01 .03*** .02*** .03*** .13*** 
        




Experiential Behavioral Readiness 
Regression 
Weights 
       
Intercept path -.31** .41*** .34*** .35*** .31*** .37*** 1.68*** 
Slope path -.05 -.05 -.04 -.06* -.03 .02 -.25*** 





Cocaine Conf and Temp  
CONCEPTUAL MODEL. 
 
The conceptual model of confidence and temptation for cocaine (see Figure 5.24) 
was first run with the complete data set and did not achieve sufficient model fit (see 
Table 5.25). Modification indices suggested covarying the confidence intercept 
(Conf_ICEPT) to the temptation intercept (Temp_ICEPT). Modification indices further 
suggested covarying time points 1 (ED1 to ER1) and 3 (ED3 to ER3). Covariances were 
then examined, showing that the paths form the confidence intercept (Conf_ICEPT) to 
the confidence slope (Conf_SLOPE) as well as the temptation intercept (Temp_ICEPT) 
to the temptation slope (Temp_SLOPE) were not significant. These non-significant paths 
indicate that participants’ rate of change over time for confidence and temptation were 
not significantly affected by where they started on either construct. Therefore, these paths 
were removed for the Level 1 model (see Figure 5.25).  
Table 5.25 
LGC Cocaine Self-Efficacy TTM Variable Modification Table 
Model 
Level 
Model Description Model X2 Df CFI RMSEA 
1 Conf & Temp      
1 Base Model (Run with no missing data) 1 127.8 26 .642 .258 
 Covaried: 
Conf ICEPT and Temp ICEPT; ED3 and ER3; 
ED1 & ER1 
Eliminated:  
Conf ICEPT and Conf SLOPE; Temp ICEPT and 
Temp SLOPE 
2 31.3 25 .978 .065 
 Complete Data Model (Run with missing data) 3 46.9 25 .924 .047 




Figure 5.24. Level 1, base model of Confidence and Temptation for cocaine 
LEVEL 1. 
 
Means from the level 1 model of confidence and temptation for cocaine showed 
that both confidence and temptations intercepts and slopes were significant. Specifically, 
participants initially reported higher levels of confidence (Estimate: 3.45, p < .001) than 
temptations (Estimate: 2.08, p < .001) and over time, participants reported significant 
increases in confidence (Estimate: .09, p = .002) and significant decreases in temptations 
(Estimate: -.06, p = .050). Covariances from this model showed that the intercept for 
confidence was negatively related to the intercept for temptation (Estimate: -.48, p < 
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.001). This indicates that participants who started at higher levels of confidence, started at 
lower levels of temptations.  
An examination of variances showed significant intercepts for both confidence 
(Estimate: .57, p < .001) and temptations (Estimate: .51, p < .001). Although the slope for 
confidence (Estimate: .03, p = .030) was also significant, the slope for temptation was 
not. This indicates that there was significant variation between participants at the starting 
points for both confidence and temptations. The slopes show that participants differed 
significantly in their rate of change for confidence over time but not for temptations. This 
variation was further explored using a predictor variable by dividing participants into 
anxiety and non-anxiety groups, as shown in the level 2 model (see Figure 5.26).   
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Figure 5.25. Level 1 model of Confidence and Temptation for cocaine 
LEVEL 2. 
 
The level 2 model of confidence and temptation for cocaine incorporates the predictor 
variable of anxiety, and regression weights were examined (see Figure 5.26). In this 
model, only the path from the anxiety variable to the intercept for temptation (Estimate: 
.42 p = .031) was significant, meaning the anxiety group initially reported higher levels 
of temptation than the non-anxiety group. However, the path from the anxiety variable to 
the intercept for confidence was not significant indicating that initially the anxiety group 
did not differ from the non-anxiety group in confidence. Furthermore, neither of the paths 
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from the anxiety variable to the slopes for confidence nor temptation were significant, 
indicating that the anxiety and non-anxiety groups did not differ significantly in their rate 
of change for either construct over time.  
 
Figure 5.26. Level 2 model of Confidence and Temptation for cocaine 
 




The conceptual model of DB for cocaine (see Figure 5.27) was first run with the 
partial data set (no missing data) and did not achieve sufficient model fit (see Table 5.26). 
Modification indices suggested covarying the pros for change intercept (DBPro_ICEPT) 
to the cons for change intercept (DBCons_ICEPT) as well as the pros for change slope 
(DBPro_SLOPE) to the cons for change slope (DBCons_SLOPE). Modification indices 
further suggested covarying time points 2 (ED2 to ER2) and 3 (ED3 to ER3). 
Covariances showed that the paths from the pros for change intercept (DBPros_ICEPT) 
to pros for change slope (DBPros_SLOPE), as well as cons for change intercept 
(DBCons_ICEPT) to cons for change slope (DBCons_SLOPE) were not significant. 
These non-significant paths indicate that participants’ rate of change over time in how 
their perceived importance of pros or cons for change was not significantly affected by 
where they started on either construct. Therefore, these paths were removed for the level 
1 model (see Figure 5.28).  
Table 5.26 
LGC Cocaine DB TTM Variable Modification Table 
Model 
Level 
Model Description Model X2 Df CFI RMSEA 
1 DB      
1 Base Model (Run with no missing data) 1 95.7 26 .573 .221 
 Covaried: 
Conf ICEPT and Temp ICEPT; Conf SLOPE and 
Temp Slope; ED3 and ER3; ED2 and ER2 
Eliminated:  
Conf ICEPT and Conf SLOPE; Temp ICEPT and 
Temp SLOPE 
2 14.9 24 1.00 .000 
 Complete Data Model (Run with missing data) 3 18.0 24 1.00 .000 




Figure 5.27. Conceptual model of Decisional Balance for cocaine 
LEVEL 1. 
Means form the level 1 model of DB for cocaine (see Figure 5.28) showed that 
both the intercepts for pros and cons for change were significant, with participants 
initially reporting greater cons for change (Estimate: 2.33, p < .001), than pros for 
change (Estimate: 1.75, p < .001). However, neither the slopes for pros nor cons for 
change were significant, meaning participants did not report significant changes in pros 
or cons for change over time. Covariances from this model showed that the intercept for 
pros for change was positively related to the intercept for cons for change (Estimate: .19, 
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p = .008). This indicates that participants who rated perceived importance in pros for 
change higher, also rated perceived importance in cons for change higher. Futhermore, 
the slopes for pros and cons for change were positively related (Estimate: .04, p < .001). 
Mean scores over time indicated that participants reported a decrease in perceived 
importance of pros and cons for change over time, suggesting that as participants 
decreased their perceived importance of pros for change, they experienced a similar rate 
of decrease in their perceived importance of cons for change.   
Variances showed that the intercepts for both pros for change (Estimate: .31, p < 
.001) and cons for change (Estimate: .44, p < .001) were significant. This indicates 
significant variation between participants at the starting points for both pros and cons for 
change. Additionally, the slopes for both pros for change (Estimate: .033, p = .003) and 
cons for change (Estimate: .44, p = .003) were significant, meaning that participants 
differed significantly in their rate of change of perceived importance of both pros and 
cons for change over time. This variation was further explored using a predictor variable 




Figure 5.28. Level 1, model 3 of Decisional Balance for cocaine 
LEVEL 2.  
 
The level 2 model incorporates the predictor variable of anxiety and regression 
weights were examined. In this model, only the path from the anxiety variable to the 
intercept for cons for change (Estimate: .66, p < .001) showed significant group 
differences. This indicates that the anxiety group initially reported higher perceived 
importance of cons for change than the non-anxiety group. The paths from the anxiety 
variable to the slopes for these constructs were not significant, meaning that the groups 
did not differ significantly in rate of change over time for pros or cons for change.  
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Figure 5.29. Level 2, model 4 of Decisional Balance for cocaine 
Cocaine Processes of Change 
CONCEPTUAL MODEL.  
 
The conceptual model of POC for cocaine (see Figure 5.30) was first run with the 
complete data set and did not achieve sufficient model fit (see Table 5.27). Modification 
indices suggested covarying the experiential processes of change intercept (EXP_ICEPT) 
to the behavioral processes of change intercept (BEH_ICEPT) as well as the experiential 
slope (EXP_SLOPE) to the behavioral slope (BEH_SLOPE). However, model fit was 
still not achieved, and modification indices further suggested covarying time points 2 
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(ED2 to ER2) and 3 (ED3 to ER3). Covariances from this model showed that the paths 
from the experiential intercept (EXP_ICEPT) to experiential slope (EXP_SLOPE), as 
well as behavioral intercept (BEH_ICEPT) to behavioral slope (BEH_SLOPE) were not 
significant. These non-significant paths indicates that participants’ rate of change over 
time in how they engaged in experiential and behavioral processes of change was not 
significantly affected by where they started on either construct. Therefore, these paths 
were removed for the level 1 model (see Figure 5.31). 
Table 5.27 
LGC Cocaine POC TTM Variable Modification Table 
Model 
Level 
Model Description Model X2 Df CFI RMSEA 
1 POC      
1 Base Model (Run with no missing data) 1 246.3 26 .537 .379 
 Covaried: 
Exp ICEPT and Beh ICEPT; Exp SLOPE and 
Beh Slope; ED3 and ER3; ED2 and ER2 
Eliminated:  
Conf ICEPT and Conf SLOPE; Temp ICEPT and 
Temp SLOPE 
2 38.3 24 .970 .100 
 Complete Data Model (Run with missing data) 3 44.5 24 .967 .047 




Figure 5.30. Conceptual model of Processes of Change for cocaine 
LEVEL 1.  
 
The means from the level 1 model of POC for cocaine (see Figure 5.31) showed 
that the experiential and behavioral intercepts were significant. Specifically, participants 
initially reported greater use of behavioral processes (Estimate: 2.70, p < .001), than the 
experiential processes (Estimate: 2.69, p < .001). However, neither the slope for the 
experiential nor the behavioral processes of change was significant, meaning participants 
did not report significant changes in their use of either the experiential or behavioral 
processes of change over time. Covariances from this model revealed that the intercept 
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for experiential processes of change was positively related to the intercept for behavioral 
processes of change (Estimate: .72, p < .001). This indicates that participants who 
initially had greater engagement in experiential processes also initially had greater 
engagement in behavioral processes. Additionally, the experiential slope was positively 
related to the behavioral slope (Estimate: .04, p < .001). An examination of mean scores 
over time indicated that participants reported a decrease in engagement with experiential 
and an increase in behavioral processes over time, meaning that when participants 
reported a decrease in their use of experiential processes, they also reported an increase 
in their use of behavioral processes.   
An examination of variances showed that the intercepts for both experiential 
(Estimate: .73, p < .001) and behavioral (Estimate: .83, p < .001) processes of change 
were significant, as were the slopes for both experiential (Estimate: .04, p < .001) and 
behavioral (Estimate: .06, p < .001) processes of change. This indicates that there was 
significant variation between participants at the starting points for both experiential and 
behavioral processes and that participants differed significantly in their rate of change for 
both processes of change over time. This variation was further explored using a predictor 
variable by dividing participants into anxiety and non-anxiety groups, as shown in the 
level 2 model (see Figure 5.32).  
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Figure 5.31. Level 1 model of Processes of Change for cocaine 
LEVEL 2.  
 
The level 2 model  of POC for cocaine (see Figure 5.32) showed that the paths from 
the anxiety variable to the intercepts for both the experiential (Estimate: .83, p < .001) 
and behavioral (Estimate: .57, p < .001) processes were significant. This indicates that 
the anxiety group reported higher use of both processes at baseline. However, the paths 
from anxiety to the slopes for the experiential and behavioral processes were not 
significant, indicating that the groups differed significantly in their rate of change for use 
of experiential and behavioral processes. 
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Figure 5.32. Level 2 model of Processes of Change for cocaine 
 
Cocaine Readiness 
CONCEPTUAL/LEVEL 1 MODEL. 
 
The conceptual model of readiness to change for cocaine (see Figure 5.33) was 
first run with the partial data set (no missing data), which produced good model fit (see 
Table 5.28). However, modification indices were examined and covariances showed the 
path from the readiness intercept (Ready_ICEPT) to the readiness slope (Ready_SLOPE) 
was not significant. Typically, this would indicate the path should be removed, however, 
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the model was examined both with and without the path for the level 2 model and model 
fit was no-longer achieved when the path was removed. Therefore, due to the lack of 
model fit without the path in the level 2 model, as well as the high model fit throughout 
the conceptual and level 1 model with the path, the path was retained. Because no 
alterations were made to the conceptual model, it also represents the Level 1 model. 
Means from this model were examined and both the readiness intercept 
(Estimate: 7.19, p < .001) and the readiness slope (Estimate: -.15, p = .046) were 
significant, indicating a significant decrease in participants’ readiness to change over 
time. Covariances from this model were also examined, but none were significant. This 
indicates that there was not a significant difference in how participants rated their initial 
readiness to change and how their readiness changed over time.  
An examination of variances showed the readiness intercept (Estimate: 5.63, p < 
.001) was significant. This indicates that there was significant variation between 
participants at the starting points for readiness. However, the readiness slope was not 
significant, indicating that participants’ readiness did not differ in rate of change over 
time. However, possible variation between groups was further explored using a predictor 
variable dividing participants into anxiety and non-anxiety groups as shown in the level 2 






LGC Cocaine Readiness TTM Variable Modification Table 
Model 
Level 
Model Description Model X2 Df CFI RMSEA 
1 Readiness      




None (Suggested but retained: Ready ICEPT and 
Ready SLOPE)  
2 7.8 8 1.00 .000 
 Complete Data Model (Run with missing data) 3 7.4 8 1.00 .000 
2 Anxiety Model 4 10.3 10 .998 .008 
 
  
Figure 5.33. Conceptual and level 1 model of Readiness for cocaine 
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LEVEL 2.  
 
In the level 2 model of readiness to change for cocaine (see Figure 5.34), only the path 
from the anxiety variable to the readiness intercept was significant (Estimate: 1.50, p = 
.010), indicating that the anxiety group reported higher readiness to change at baseline 
than the non-anxiety group. Because the path from the anxiety variable to the readiness 
slope was not significant, the  anxiety and non-anxiety groups do not appear to differ on 
reported rate of change over time in their readiness to change.   
 
Figure 5.34. Level 2 model of Readiness for cocaine 
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To aid in interpretation of the LGC results from the TTM constructs listed above (i.e., 
confidence and temptation, pros and cons of change, experiential and behavioral 
processes of change, and readiness to change) Table 5.29 presents a summary of LGC 
findings for cocaine.  
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Table 5.29 
LGC Summary Table of TTM constructs for cocaine 




Experiential Behavioral Readiness 
Means         
Intercept 3.45*** 2.08*** 1.75*** 2.33*** 2.70*** 2.70*** 7.20*** 
Slope .09** -.06* -.01 -.02 -.02 .02 -.15* 
Covariance        




Estimate -.48*** .04*** .72*** 
Slope None Pros <-->Cons Exp <-->Beh 
Estimate -- .19** .04*** 
Variance        
Intercept .57*** .51*** .31*** .44*** .73*** .83*** 4.56*** 
Slope  .03** .01 .03** .06** .04*** .06*** .08 
        




Experiential Behavioral Readiness 
Regression 
Weights 
       
Intercept path -.30 .42* .25 .66** .73*** .83*** 1.50** 
Slope path  -.03 -.01 -.07 -.03 .04*** .06*** -.09 
Note:  p = * < .05, ** < .01, *** < .001. Level 2 values are derived from unstandardized regression weights. 
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VI. DISCUSSION 
SUDs and ADs are highly prevalent among adults in the United States and each 
contributes to significant health, financial, and social problems around the world. Alcohol 
and illicit drug use, including marijuana, are associated with substantial burden through 
impairment in major life roles and increased risk for suicidality, neuropsychological 
deficits, diminished quality of life, and infectious disease (e.g., human immunodeficiency 
virus and hepatitis) (Grant, Saha, Ruan, et al., 2016). In addition, systematic reviews of 
yearly and lifetime prevalence showed that those diagnosed with anxiety disorders also 
often experience significant life altering impairments (Baxter, Scott, Vos, & Whiteford, 
2012).  
Given that SUDs and ADs are some of the most prevalent psychological disorders, it 
is not surprising to find that these conditions often co-occur, and exacerbate each other 
(Conway, Swendsen, Husky, He, & Merikangas, 2016). Moreover, when found together, 
each disorder may significantly hinder treatment of the other, especially considering that 
those with a comorbid SUD and AD are significantly less likely to seek or accept care for 
either disorder (Melchoir, Prokofyeva, Younes, Surkan, & Martins, 2014). As a result of 
these significant concerns, researchers and clinicians have been working to further 
understand and better treat comorbid SUD and AD. It has therefore been the aim of this 
dissertation to further understand how these disorders impact each other. This dissertation 
specifically focused on the effects of anxiety on substance use outcomes, and examined 
differences in the process of change regarding substance use for those with and without 
clinically significant levels of anxiety. This dissertation also aims to provide 
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recommendations for future research and clinical care regarding the treatment of these 
co-occurring disorders.  
The transtheoretical model has provided a sturdy platform to study both the behaviors 
and treatments of these disorders. Using TTM, this dissertation examined two areas of 
interest. The first was to identify if the presence of anxiety impacts substance use 
outcomes over time. In other words, do people with anxiety experience the same 
reduction in substance use over time compared to those without anxiety. The second was 
to examine if the process of changing drug use differed for those with anxiety compared 
to those who do not endorse anxiety, using the transtheoretical model. For instance, do 
those without anxiety identify greater levels of confidence in their ability to remain 
abstinent throughout treatment than those with anxiety?  
Anxiety’s Impact on Substance Use Outcomes 
Researchers have consistently found that when ADs and SUDs co-occur, 
individuals are more likely to report greater substance use prior to treatment, as well as 
higher rates of relapse throughout and after treatment (Driessen et al., 2001; Ouimette et 
al., 1997) Based on this and other current literature cited in the initial chapters of this 
dissertation, it was hypothesized that individuals who endorse anxiety would be more 
likely to endorse higher substance use at four different time points (baseline, 3-, 6-, and 
12-month follow-ups). 
Several analyses were preformed to test these assumptions, including baseline T-
tests and repeated measures analyses of four substance categories (alcohol, cannabis, 
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cocaine, and any drug), at the four different time points. Findings from these analyses 
generally supported conclusions from the previous literature with a few exceptions. 
While findings from this study were consistent in showing that participants with anxiety 
reported greater alcohol and cocaine use at intake and generally throughout the next three 
time points, this was not the case for those who used cannabis or when any drug use was 
the variable of interest. Rather, there was no discernable difference in substance use 
between the anxiety and non-anxiety groups in the any drug use category; and for those 
who used cannabis, the anxiety group actually reported more days abstinent at baseline 
than the non-anxiety group. These findings were further supported through the repeated 
measures analysis showing the anxiety group reported more PDA from cannabis use at 
baseline, 3 months, and at 12 months.  
The initial differences between substance use by those with anxiety compared to 
those without, as well as the consistency of substance use patterns over time between the 
anxiety and non-anxiety groups comparatively, suggests that anxiety’s influence on 
substance use is likely drug specific. For instance, while much of the previous research 
found that comorbid participants had higher substance use at the start of treatment 
(Trafton, Minkel, and Humphres, 2006; (Mills, Teesson, Ross, & Darke, 2007; Farris, 
Epstein, McCrady, & Hunter-Reel, 2012), these findings may be limited by the fact that 
studies have largely focused on alcohol, cocaine, and opioid use. This highlights a gap in 
the literature, since studies focusing on anxiety and cannabis, and other substances such 
as cocaine and methamphetamines, remains sparse.  
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One reason for the divergent findings for cannabis use compared to alcohol and 
cocaine use between the two groups at baseline may be that cannabis may have 
effectively reduced anxiety in some users (Bergamaschi et al., 2011). It is possible that 
cannabis  effectively helped some participants manage their anxiety symptoms prior to 
the study. If this is true, participants who self-medicated anxiety symptoms through 
cannabis use may not have endorsed enough symptomology on the BSI to be placed in 
the anxiety group. Therefore, some cannabis participants who should have been in the 
anxiety group, may have actually been placed in the non-anxiety group.  
Another possible reason for this divergence is the opposite, that for some people 
cannabis use can actually exacerbate acute anxiety symptoms (Degenhardt, Hall, & 
Lynskey, 2001). In this case, cannabis use is reduced since it makes their anxiety worse. 
For example, in one study, participants in treatment for panic disorder reported more 
feelings of anxiety following cannabis use compared to those in treatment for depression 
and control groups (Szuster, Pontius, & Campos, 1988). Similar to cannabis, many other 
substances may also have negative effects on anxiety sufferers. In sum, those with 
anxiety are likely to over indulge in substances that have a medicating effect on their 
symptoms, while avoiding substances that exacerbate symptoms.  
As for the category of any drug use, after examining findings it was clear that 
when analyzed all-together, group differences in the many different substances averaged 
out and no significant difference between anxiety and non-anxiety participants could be 
identified. Therefore, future studies should account for anxiety’s impact on specific 
substances, rather than lump all substance use together.  
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Finally, while, on average, study participants reduced overall substance use  by 
the final time point, there were group differences based on the drug examined. For 
example, by the final time point, alcohol and cocaine use did not significantly differ by 
anxiety group, but cannabis use did. Other results also differed by drug type. For 
example, cannabis and alcohol each showed significant group differences at three of the 
four time points, but cocaine use differed by group difference at only one time point, 
baseline. And no group differences were observed at any of the four time points for any 
drug use. Lastly, repeated measures analysis revealed that, of the four substance use 
categories, only cocaine had a significant substance use by anxiety group interaction 
across time. In other words, of the four substance use categories, it was only for cocaine 
that anxiety seemed to play a significant role in the actual change of substance use 
outcomes over time. Again, this points to the notion that anxiety’s impact on substance 
use is drug specific suggesting that researchers should examine anxiety’s relationships 
with each drug type separately.  
Anxiety’s Impact on the Process of Changing Substance Use 
The second aim of this paper was to describe the impact of anxiety on the overall 
process of changing substance use behaviors, in accordance with the transtheoretical 
model (TTM). Studies have shown that progression through the processes of change for 
substance abusers consist of moving through a series of steps or phases, each of which 
address different issues and may require different strategies (DiClemente & Prochaska, 
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1998; DiClemente, Prochaska, & Gibertini, 1985; DiClemente et al., 1991; Prochaska et 
al., 1991, 1992; Prochaska Velicer, et al., 1994; Smit et al., 1995; Velasquez et al., 1999).  
More to the point, movement toward change does not seem to come from repeating, 
or even increasing any one thing, rather it comes from emphasizing distinct change 
promoting elements throughout the process, depending on the behavior/substance that is 
targeted. For example, while promoting increased perceived importance of pros for 
change over cons for change may be valuable in the early stages of change, such as 
precontemplation and contemplation, too much focus on this instead of other change 
tactics may stifle advancement through later stages of change.  
There are, however, some nearly universal process markers that indicate an 
individual is on track for successful change (Carbonari & DiClemente, 2000). According 
to previous work with the TTM, successful change elements tend to include: greater 
motivation or readiness to change, lower temptation to use a substance, higher confidence 
to abstain, higher ratings of pros for change and lower ratings cons for change, and use of 
the experiential and behavioral change processes (Prochaska, DiClemente, & Norcross, 
1992; DiClemente & Carbonari, 1996).  
With this understanding, it was predicted that different TTM construct profiles would 
emerge between those with and without anxiety for each substance use category. To this 
end, GLM profile analyses and latent growth curve analyses were performed for both 
cannabis and cocaine users in hopes of identifying distinct profiles and patterns of change 
using TTM constructs based on anxiety groupings. Findings generally supported these 
expectations.  
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First, there were distinct differences in the profiles of the cocaine and cannabis 
groups. Differences in both the overall TTM profiles and patterns of engagement with the 
TTM constructs were evident between the two groups. For instance, LGC analyses 
showed the two groups differed across all constructs initially and that the anxiety group’s 
perceived importance of cons for change and readiness to change declined more slowly 
than the non-anxiety group over time.  
Meanwhile, profile analyses showed that the anxiety group initially had higher 
contemplation, action, and maintenance scores; endorsed higher perceived importance 
for pros (except for cocaine users) and cons for change; reported lower confidence in 
their ability to change and greater temptation to continue engaging in the problem 
behavior; but endorsed greater use of both the experiential and behavioral processes of 
change compared to the non-anxiety group. Based on the profile differences between the 
groups at baseline, literature suggests that the anxiety group was poised to reduce their 
substance use at a greater rate than the anxiety group.  
For instance, in looking at cannabis users, the anxiety group initially used less 
substance use compared to the non-anxiety group, had higher scores in each of the stages 
of change beyond pre-contemplation (contemplation, preparation, action, and 
maintenance), reported higher engagement in the decisional balance process (perceived 
importance of pros and cons), and engages more in the processes of change (experiential 
and behavioral). Conversely, the non-anxiety group has higher scores in the pre-
contemplation stage, and less engagement in both decisional balance and processes of 
change.  
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All of these group differences indicate the anxiety group has higher overall readiness 
to change at baseline compared to the non-anxiety group. In fact, although not all 
constructs remain significant throughout the study, the pattern of the profiles remains 
consistent over the next three time points, and the anxiety group maintains a higher 
readiness to change over the non-anxiety group at all four time points. However, when 
outcome results are reviewed, a critical finding emerges. Although profile differences 
between groups would seem to indicate the anxiety group should have greater success in 
reduction of substances, there was no difference in rate change of substance use between 
the two groups. Although both the anxiety group and non-anxiety group significant 
reduced substance use over time, neither group reduced their use at a greater rate.  
Given these findings, the question looms, if the anxiety group demonstrates a greater 
readiness to change, why does it change at the same rate as the non-anxiety group? To 
answer this question, it is important to look at each TTM construct, especially those of 
confidence and temptation, where across the four time points, the anxiety group reported 
significantly lower confidence in their ability to change and greater temptations to return 
to using compared to the non-anxiety group. A further understanding of the lack of 
differentiation in substance use change between groups can be found by specifically 
examining the final time point for the cannabis users. At this 12-month time point, the 
anxiety group reported significantly higher scores in contemplation, temptations to use, 
and both the experiential and behavioral processes of change. This seems to indicate that 
the anxiety group had difficulty progressing beyond the contemplation stage, even by the 
12-month mark.  
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One explanation of lack of progression beyond the contemplation stage offered 
through TTM literature is that progression beyond the contemplation stage is largely 
based on decisional balance, or how a participant perceives pros and cons for change 
(Prochaska, Redding, Harlow, Rossi, & Velicer, 1994). Generally, progression through 
the stages begins with increased importance placed on pros for change compared to cons 
for change (specifically in the contemplation stage), followed by an overall decrease in 
importance of both pros and cons for change as the participant successfully moves into 
different stages of change (Connors et al., 2013). However, findings from this dissertation 
showed that while both groups showed a reduction in perceived importance of pros and 
cons for change over time, which would indicate the client is progressing onto the next 
stages of change (action or maintenance), the anxiety group’s perceived importance of 
cons for change decreased at a lower rate than the non-anxiety group.  
This is noteworthy because literature suggests that as an individual progresses 
through the stages of change, particularly beyond contemplation, there is generally a 
reduction of perceived importance place on both pros and cons for change (Connors et 
al., 2013). This reduction occurs because the individual has determined that the pros for 
change sufficiently outweigh the cons for change, likely because the perceived benefits of 
change outweigh the negative aspects of continuing the behavior, and the individual 
moves beyond considerations of pros and cons. However, in this case the anxiety group 
seemed to maintain their contemplation of the perceived importance of these pros and 
cons beyond the non-anxiety group. Thus, the anxiety group maintained a state of 
contemplation through ambivalence.  
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Another observed group difference was found in processes of change. The literature, 
specifies ten processes of change, five experiential and five behavioral (Connors et al., 
2013). The primary difference between the experiential and behavioral processes is that 
the experiential processes are cognitive and affective while the behavioral processes 
require behavioral engagement (Velasquez, Crouch, Stephens, & DiClemente, 2016; 
Velicer, Prochaska, Fava, Norman, & Redding, 1998). Because the experiential processes 
of change are more thought driven, they are typically observed during the early part of 
behavior change when a person is debating whether to make a change or not, such as 
when the individual is in the contemplation stage (Velicer, Prochaska, Fava, Norman, & 
Redding, 1998). As the individuals moves into the preparation and action stages, they 
increase their engagement in the more active behavioral processes, such as changing their 
environment or substituting new behaviors for the one they are attempting to change 
(Velicer, Prochaska, Fava, Norman, & Redding, 1998). Though this is the typical 
situation, anxiety participants in this study were still engaging in the experiential 
processes at nearly the same rate as the behavioral processes. 
In addition to anxiety participants suboptimal progression in processes of change, 
their lack of self-efficacy was also evident. Across all four time points the anxiety group 
consistently reported lower levels of confidence and greater levels of temptations. As 
literature has shown that self-efficacy is directly correlated with participants movement 
from pre-contemplation through all other stages including maintenance (Prochaska et al., 
1991), anxiety participants’ lack of self-efficacy may be the most important reason that 
they are not more successful in reducing substance use. 
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The observed TTM construct differences between the anxiety and non-anxiety 
groups, (i.e., pros and cons of change, confidence and temptation, and overall readiness 
to change) were first identified through profile analyses (PA). Although these 
observations were distinctly important, the confirmation of these differences through 
latent growth curve (LGC) analyses, which is a far more sensitive analysis for changes 
over time, is invaluable. For instance, LGC compared both groups together over time and 
confirmed that these differences, which were observed initially in PA, were also 
maintained over the 12 months of study. These findings together provide a strong basis 
for the assertion that self-efficacy and decisional balance are key factors for the lack of 
greater reduction of substance use that might otherwise have been observed for the 
anxiety group compared to the non-anxiety group.  
Profile Differences Between Substances   
An unexpected finding that emerged from this dissertation highlighted differences 
between the anxiety and non-anxiety groups based on substance use categories. While the 
shapes of the TTM profile patterns for the anxiety and non-anxiety group remained 
relatively similar for both cannabis and cocaine, differences of which, and how many, of 
the TTM constructs were significantly different over the four time points between the 
groups emerged for cannabis and cocaine. For instance, while both cannabis and cocaine 
showed nearly all TTM constructs to be significantly different between anxiety groups at 
baseline (9/10 significant constructs for cannabis and 8/10 for cocaine), by the 3-month 
time point, 8/10 constructs remained significant for cannabis, while only 2/10 constructs 
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were significant for cocaine. However, the differences between the substances seemed to 
dissipate by the final time point where both cannabis and cocaine each showed 4/10 
constructs to be significant, though, the constructs themselves were different.  
A possible explanation for the differences in profiles between the cannabis and 
cocaine users is that fewer participants used cocaine (n=86) than cannabis (n=310). Thus, 
statistical power due to the small sample size of the cocaine group may have been 
insufficient to detect differences between groups for each construct. Additionally, when 
reviewing substance outcomes, a large number of cocaine users reported a high percent of 
days abstinent, making it difficult to identify any real reduction in use over time. In other 
words, there may have been a ceiling effect for the cocaine group that was not apparent in 
the cannabis group. Lastly, it should be noted that most of the cocaine participants also 
endorsed cannabis use, and it is possible that these participants chose to focus on 
changing one substance over the other. Therefore, given the limiting conditions for 
cocaine, the following comments focus largely on cannabis profile results, as they seem 
to provide a clearer picture of change.  
Ultimately, this study found that anxiety participants were as successful as non-
anxiety participants in reducing their substance use at the 12-month follow-up. However, 
anxiety participants engaged with the TTM variables differently than non-anxiety 
participants. This was especially notable with the processes of change and self-efficacy 
variables. While anxiety participants did engage more in both experiential and behavioral 
processes of change, they seemed to over utilize experiential processes of change 
compared to behavioral processes at later time points. In addition, anxiety participants 
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reported lower confidence and greater temptation, effectively diminishing progress which 
may have promoted change. In summary, though both groups experiencing a similar 
reduction rate of substance use, anxiety participants engaged TTM variables differently 
than the non-anxiety participants.  
Implications for Practice  
 Given that individuals diagnosed with both a SUD and an AD are prone to worse 
outcomes and generally benefit less from treatment, this study suggests modifications in 
treatment regimens could improve treatment outcomes and mark a significant step 
forward in comorbid care. First, this dissertation indicates that anxiety’s impact on 
substance use outcomes were clearly dependent on the type of substance used. While 
anxiety participants initially reported increased cocaine and alcohol use compared to non-
anxiety participants, the anxiety group reported less initial cannabis use than the non-
anxiety group. Therefore, clinicians should consider current research pertaining to each 
substance to guide best treatment practices.  
Next, this dissertation shows that while clients with anxiety may reduce substance use 
over time at rates similarly to those without anxiety, there are clear differences between 
how the two groups engage in TTM constructs and change over time. The anxiety group 
had higher scores in contemplation, lower confidence in their ability to change, and 
greater susceptibility to temptations to return to use. Taken together, this seems to have 
resulted in a perpetuation of ambivalence throughout months of the study, despite high 
motivations to change.  
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Put another way, while the anxiety group participants clearly showed a higher 
readiness to change from the beginning to the end of the study, their lack of confidence in 
their ability to change in the face of significant temptations to use likely tempered their 
overall improvement. Therefore, by helping those with anxiety increase their self-efficacy 
(confidence) and effectively address temptations to use, they could move from the 
contemplation stage and into the more action-oriented stages and achieve greater 
reductions in substance use. Therefore, clinicians should target self-efficacy early and 
often when treating anxiety sufferers. 
This finding also helps to answer an important question identified in this dissertation: 
Which of the three primary treatment approaches (sequential, parallel, or concurrent), is 
most effective in treating substance use and anxiety disorders? As this dissertation 
suggests that the primary factor limiting effective treatment of those with these comorbid 
disorders was that individuals were unable to progress beyond contemplation due to a 
lack of self-efficacy, it seems logical that by first addressing this lack of self-efficacy, 
patients would improve in their substance use care. Therefore, it seems that initially a 
sequential treatment model where anxiety is treated first would be most ideal. However, 
another concern must be discussed before drawing this conclusion.  
While treating anxiety first may increase self-efficacy, there is also the potential that 
engagement in anxiety treatment could exacerbate symptomology (especially in cases of 
PTSD), which might further drive patients to self-medicate through substance use. 
Moreover, by delaying substance use treatment, the client is potentially left facing mortal 
danger through the continued effects of the substance or possibly an overdose. With these 
 134 
concerns in mind, the findings of this study suggest that a concurrent treatment model be 
used in treating those with comorbid anxiety and substance use disorders.  
Implications for the Military  
Because military members report higher prevalence rates of both anxiety and 
substance use, one benefit of this dissertation is that its findings are potentially applicable 
to military personnel, particularly the findings for the anxiety group. Findings that 
anxiety participants showed potential for even greater rates of improvement, so long as 
treatments are able to target self-efficacy concerns, is highly encouraging for military 
treatment programs. If military models treat some of the negative characteristics tied to 
anxiety, such as a lack of confidence, while concurrently treating substance use 
behaviors, military members are far more likely to internalize treatment and experience 
long-term benefits.  
However, this study does not address some characteristics unique to the military 
population. For example, this study does not account for external factors, including 
coercive treatment methods such as mandated treatment models, in substance use 
outcomes. Since many military members (particularly active duty service members) must 
comply with treatment guidelines or face expulsion from the military, or possibly worse, 
such as confinement in a military prison, these external motivators are likely to have 
significant effects on treatment for this population and require further examination. A 
2010 study by Ondersma, Winhusen, and Lewis found that external motivators, including 
potential incarceration, loss of child custody, and/or loss of subsidized housing, 
 135 
effectively increased retention during treatment, and positively influenced substance use 
outcomes after 12 weeks. Therefore, it is likely that military participants mandated 
treatment will initially fair at least as well, if not better than participants in this study.  
However, another study that examined the impact of external motivators on 
change conducted by Stotts and colleagues (1996), found something different. In this 
study, smoking cessation was examined comparing pregnant and non-pregnant smokers. 
Findings revealed that participants who relied on heavy external motivators to change 
(the health of an unborn baby), experienced significantly higher relapse rates than 
participants without such external motivators for change. Ultimately, although the 
pregnant smokers were able to move quickly into the action stage of change, they 
continually under-endorsed experiential and behavioral processes of change.  
Clinicians should therefore be mindful of external factors in the military that may 
seem to facilitate change, but in reality, do not provide a lasting effect (such as mandated 
substance use treatment with the consequence of discharge looming as a consequence of 
failure). Instead, when working with a population that is heavily influenced by external 
motivators, clinicians must augment treatment in a way that capitalizes on the increased 
participation yielded through external motivators, while also supplanting external 
motivators with internal desires for change.  
Lastly, it is important to note that because this study did not focus on any single 
type of anxiety, the findings cannot be considered generalizable to particular anxiety 
disorders. This is an important distinction because those who have served in and around 
the military are more prone to some types of anxiety including PTSD, than the general 
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population. Since this study indicated that anxiety’s impact on substance use outcomes is 
drug specific, and because study limitations preclude identifying different anxiety 
disorders would impact each type of substance use, the impacts of various anxiety 
disorders on each of the various substances should be studied. In particular, researchers 
should examine PTSD’s effects on alcohol use, as these comorbid diagnoses are highly 
prevalent among this population.  
Limitations and Future Research Directions  
This study is a step forward in understanding the relationship between anxiety and 
substance use disorders. However, several limitations of this study must be noted, along 
with recommendations of addressing them. First, while study findings are likely 
applicable to populations with similar demographic characteristics (younger Caucasian 
males, such as the military), results are not generalizable to the general population, which 
is far more diverse. Therefore, future research should target other populations in other 
environments.  
Second, available data were limited for each substance. TTM construct data for 
alcohol was not obtained during the initial Project TIP study, making it impossible to 
compare the cocaine and cannabis findings with alcohol. Third, this study was also 
limited by the small sample size for cocaine (n=86), which made comparisons with 
cannabis difficult. Because alcohol and cocaine are such commonly used substances, a 
replication of this study using these and many other substances is needed.  
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Fourth, this study was based on a broad identification of anxiety symptoms using BSI 
subscale cutoff scores but was unable to specify or compare various anxiety disorders. 
Knowledge of how different anxiety disorders impact different substance would have 
substantial benefits for treatment planners. For example, future research for the military 
should examine the impact of anxiety disorders such as PTSD on substance use such as 
alcohol as these are commonly occurring disorders among service members.  
Fifth, much of the study data relied on self-report, both for anxiety and for alcohol 
use via Time Line Follow Back (TLFB) procedures. Although self-report is considered 
an acceptable method of gathering data for these types of studies (Carey, Maisto, Carey, 
& Pumine, 2001), there are also weaknesses of self-report data. Participant must 
demonstrate a certain level of introspective ability, and even in cases where the 
participant desires to respond honestly, some may lack awareness (possibly due to recall 
bias) required to provide accurate accounts of behaviors. Additionally, self-report 
measures are susceptible to desirability bias, which drives responders to ascribe more 
positive traits to themselves, responding in ways that makes them appear more favorable 
(Nederhof, 1985).  
Topics such as comorbid mental health diagnoses and substance use are particularly 
susceptible to social desirability bias (Furnham, 1986). Despite these drawbacks, self-
report measures are a cost-effective way to gather large amounts of information from 
participants, as required in this study. Accordingly, this dissertation benefits from a 
strength of the TIP study, which accounted for these concerns by performing a 
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biochemical validation of substance use, results of which demonstrated congruency with 
self-reported use. 
 Lastly, although repeated measures analyses were able to compare anxiety and 
non-anxiety groups, neither profile nor latent growth curve analyses using TTM 
constructs were linked to substance use outcomes by group comparisons. Thus it was 
impossible to extrapolate a “successful profile” for those who reduced substance use 
compared to those who did not. Developing such a profile is another recommended action 




 This dissertation set out to increase understanding of the complex relationships 
between anxiety disorders and substance use disorders. It began by identifying two 
significant gaps in the research. The first was that researchers have not sufficiently 
described anxiety’s impact on substance use outcomes. Secondly, researchers have yet to 
examine how individuals with anxiety experience change regarding substance use 
compared to those without anxiety. Through t-tests, general linear model repeated 
measures and profile analyses, and, finally, latent growth curve analyses, this study is 
among the first to examine these concerns using TTM constructs.  
Despite the study’s limitations, the findings increase our understanding of the 
complex relationship between anxiety and substance use. One key finding was that 
anxiety’s impact on substance use before, during, and following treatment is dependent 
on the drug being examined. This finding provides much needed guidance by directing 
future research to compare specific substances rather than lumping all substances into a 
single category. Another key finding was that anxiety and non-anxiety groups 
experienced change in different ways based on TTM constructs, also depending on the 
substance used, further emphasizing the need for researchers to be mindful of these 
differences.  
A last key take-away is that there are distinct differences in how anxiety and non-
anxiety participants engaged in the change process. Through a close examination of these 
differences, it seemed that, while both groups reduced substance use at a similar rate, the 
anxiety group potentially could have changed at a far greater rate by addressing self-
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efficacy concerns early in treatment. This suggests that clinicians should avoid the “one 
size fits all” approach and tailor treatment regimens for those with anxiety. Specifically, 
in addition to assessing motivations to change, treatment providers should promote a 
client’s or patient’s self-efficacy throughout treatment to maximize gains for this 
population. Although this dissertation does not answer every question about the 
relationship between anxiety and substance abuse, it does provide valuable information 
for researchers and clinicians interested in helping those with co-occurring substance use 




Anxiety disorder criteria 
Adjustment 
Disorders 
DSM-IV-TR Adjustment Disorder diagnostic criteria (APA, 2001): 
 A. The development of emotional or behavioral symptoms in response to an 
identifiable stressor(s) occurring within 3 months of the onset of the stressor(s).  
B. These symptoms or behaviors are clinically significant as evidenced by 
either of the following:  
(1) marked distress that is in excess of what would be expected from exposure 
to the stressor  
(2) significant impairment in social or occupational (academic) functioning  
C. The stress-related disturbance does not meet the criteria for another 
specific Axis I disorder and is not merely an exacerbation of a preexisting Axis 
I or Axis II disorder.  
D. The symptoms do not represent Bereavement.  
E. Once the stressor (or its consequences) has terminated, the symptoms do 
not persist for more than an additional 6 months.  
Specify if:  
Acute: if the disturbance lasts less than 6 months  
Chronic: if the disturbance lasts for 6 months or longer Adjustment Disorders are 






DSM-IV-TR GAD diagnostic criteria (APA, 2001):  
A. Excessive anxiety and worry (apprehensive expectation), occurring more 
days than not and for at least 6 months, about a number of events or activities (such as 
work or school performance) 
B. The person finds it difficult to control the worry 
C. The anxiety and worry are associated with three (or more) of the following 
six symptoms (with at least some symptoms present for more days than not for the past 
6 months). Note: only one item is required in children  
(1) restlessness or feeling keyed up or on edge 
(2) being easily fatigued 
(3) difficulty concentrating or mind going blank 
(4) irritability 
(5) muscle tension 
(6) sleep disturbance (difficulty falling or staying asleep, or restless 
unsatisfying sleep) 
D. The focus of the anxiety and worry is not confined to features of an Axis I 
disorder. E.g., the anxiety or worry is not about having a panic attack (as in panic 
disorder), being embarrassed in public (as in social phobia), being contaminated (as in 
obsessive compulsive disorder), being away from home or close relatives (as in 
separation anxiety disorder), gaining weight (as in anorexia nervosa), having multiple 
physical complaints (as in somatization disorder), or having serious illness (as in 
hypochondriasis), and the anxiety and worry do not occur exclusively during 
posttraumatic stress disorder. 
E. The anxiety, worry, or physical symptoms cause clinically significant 
distress or impairment in social, occupational, or other important areas of functioning. 
F. The disturbance is not due to the direct physiological effects of a substance 
(e.g, a drug of abuse, a medication) or general medical condition (e.g., 
hyperthyroidism) and does not occur exclusively during a mood disorder, a psychotic 
disorder or a pervasive developmental disorder.  
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SAD  DSM-IV-TR Social Anxiety Disorder (SAD) criteria (APA, 2001): 
A. Marked and persistent fear of one or more social or performance situations 
in which the person is exposed to unfamiliar people or to possible scrutiny by others. 
The individual fears that he or she will act in a way (or show anxiety symptoms) that 
will be humiliating or embarrassing. Note: In children, there must be evidence of the 
capacity for age-appropriate social relationships with familiar people and the anxiety 
must occur in peer settings, not just in interactions with adults. 
B. Exposure to the feared social situation almost invariably provokes anxiety, 
which may take the form of a situationally bound or situationally predisposed panic 
attack. Note: In children, the anxiety may be expressed by crying, tantrums, freezing, 
or shrinking from social situations with unfamiliar people. 
C. The person recognizes that the fear is excessive or unreasonable. Note: In 
children, this feature may be absent. 
D. The feared social or performance situations are avoided or else are endured 
with intense anxiety or distress. 
E. The avoidance, anxious anticipation, or distress in the feared social or 
performance situation(s) interferes significantly with the person's normal routine, 
occupational (academic) functioning, or social activities or relationships, or there is 
marked distress about having the phobia. 
F. In individuals under the age of 18, the duration is at least 6 months. 
G. The fear or avoidance is not due to the direct physiological effects of a 
substance (e.g., drug abuse, a medication) or a general medical condition and is not 
better accounted for by another mental disorder (e.g., panic disorder with or without 
agoraphobia, separation anxiety disorder, body dysmorphic disorder, a pervasive 
developmental disorder, or schizoid personality disorder). 
H. If a general medical condition or another mental disorder is present, the 
fear in Criterion A is unrelated to it, e.g., the fear is not of stuttering, trembling in 
Parkinson's disease, or exhibiting abnormal eating behavior in anorexia nervosa or 
bulimia nervosa. 
Specify if: 
Generalized: if the fears include most social situations (also consider the 
additional diagnosis of avoidant personality disorder). 
Panic 
Disorders 
DSM IV-TR Panic Disorder (PD), with (and without) agoraphobia, criteria (APA, 
2001): 
A. Both (1) and (2) 
1. Recurrent unexpected Panic Attacks 
2. At least one of the attacks has been followed by 1 month (or more) of one 
(or more) of the following: 
a. Persistent concern about having additional attacks 
b. Worry about the implications of the attack or its consequence (e.g., losing 
control, having a heart attack, ‘‘going crazy’’) 
c. A significant change in behavior related to the attacks 
B. The presence (or absence) of Agoraphobia 
C. The panic attacks are not due to the direct physiological effects of a 
substance (e.g., a drug of abuse, a medication) or a general medical condition (e.g., 
hyperthyroidism) 
D. The panic attacks are not better accounted for by another mental disorder, 
such as social phobia (e.g., occurring on exposure to feared social situations), specific 
phobia (e.g., on exposure to a specific phobic situation), obsessive–compulsive 
disorder (e.g., on exposure to dirt in someone with an obsession about contamination), 
Posttraumatic stress disorder (e.g., in response to stimuli associated with a severe 
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DSM IV-TR Panic Attack (PA) criteria (APA, 2001): 
A discrete period of intense fear or discomfort, in which four (or more) of the 
following symptoms developed abruptly and reached a peak within 10 min.  
1. Palpitations, pounding heart, or accelerated heart rate 
2. Sweating 
3. Trembling or shaking 
4. Sensations of shortness of breath or smothering 
5. Feeling of choking 
6. Chest pain or discomfort 
7. Nausea or abdominal distress 
8. Feeling dizzy, unsteady, lightheaded, or faint 
9. Derealization (feelings of unreality) or depersonalization (being detached 
from oneself) 
10. Fear of losing control or going crazy 
11. Fear of dying 
12. Paresthesias (numbness or tingling sensations) 






DSM IV-TR Post-Traumatic Stress Disorder (PTSD), criteria (APA, 2001): 
A. The person has been exposed to a traumatic event. 
B. The traumatic event is persistently re-experienced in one (or more) of the 
following ways: 
• Recurrent and intrusive distressing recollections of the event, including 
images, thoughts, or perceptions.  
• Recurrent distressing dreams of the event.  
• Acting or feeling as if the traumatic event were recurring (includes a sense 
of reliving the experience, illusions, hallucinations, and dissociative 
flashback episodes, including those that occur on awakening or when 
intoxicated).  
• Intense psychological distress at exposure to internal or external cues that 
symbolize or resemble an aspect of the traumatic event.  
• Physiological reactivity on exposure to internal or external cues that 
symbolize or resemble an aspect of the traumatic event.  
C. Persistent avoidance of stimuli associated with the trauma and numbing of 
general responsiveness (not present before the trauma), as indicated by three (or more) 
of the following: 
• Efforts to avoid thoughts, feelings, or conversations associated with the 
trauma.  
• Efforts to avoid activities, places, or people that arouse recollections of the 
trauma. 
• Inability to recall an important aspect of the trauma.  
• Markedly diminished interest or participation in significant activities.  
• Feeling of detachment or estrangement from others.  
• Restricted range of affect (e.g. unable to have loving feelings).  
• Sense of a foreshortened future (e.g., does not expect to have a career, 
marriage, children, or a normal life span).  
D. Persistent symptoms of increased arousal (not present before the trauma), 
as indicated by two (or more) of the following:  
• Difficulty falling or staying asleep.  
• Irritability or outbursts of anger.  
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• Difficulty concentrating. 
• Hypervigilance.  
• Exaggerated startle response.  
E. Duration of the disturbance (symptoms in Criteria B, C, and D) is more 
than 1 month.  
F. The disturbance causes clinically significant distress or impairment in 
social, occupational, or other important areas of functioning.   
Specify if: Acute: if duration of symptoms is less than 3 months Chronic: if 
duration of symptoms is 3 months or more Specify if: With Delayed Onset: if onset of 
symptoms is at least 6 months after the stressor. 
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